<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Palmoplantar keratoderma</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Palmoplantar keratoderma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Palmoplantar keratoderma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Akiharu Kubo, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer L Hand, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 30, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2781901324"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Palmoplantar keratoderma (PPK) is a heterogeneous group of inherited or acquired disorders characterized by excessive epidermal thickening of the palms and soles. Hereditary PPKs are in most cases caused by mutations in genes encoding proteins that are components of the intracellular cytoskeleton (eg, keratins) or involved in intercellular adhesion (eg, desmosomal proteins), cell-to-cell communication (eg, connexins), and cell signaling (eg, SLURP1) [<a href="#rid1">1,2</a>].</p><p>Hereditary PPKs can occur in isolation (nonsyndromic PPK) or in association with extracutaneous manifestations (syndromic PPK) [<a href="#rid1">1,3,4</a>]. PPK can also be a manifestation of a broad number genodermatoses, including inherited ichthyoses, inherited blistering diseases, and ectodermal dysplasias.</p><p>The diagnosis of a specific PPK type is challenging, due to the highly heterogeneous phenotypes and genotypes, and is based on a combination of clinical and histopathologic features and genetic testing [<a href="#rid5">5</a>].</p><p>This topic will focus on inherited nonsyndromic PPKs and syndromes in which PPK is a major feature. Other inherited disorders of keratinization that may present with PPK are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15465.html" rel="external">"Overview and classification of the inherited ichthyoses"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15449.html" rel="external">"Epidermolysis bullosa: Epidemiology, pathogenesis, classification, and clinical features"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/110146.html" rel="external">"Ectodermal dysplasias"</a>.)</p><p></p><p class="headingAnchor" id="H440272964"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The exact incidence and prevalence of PPKs are unknown. In Northern Ireland, the estimated prevalence of epidermolytic PPK (PPK Vörner type), the most common type of PPK, was 4.4 per 100,000 [<a href="#rid6">6</a>]. In Japan and China, the estimated prevalence of PPK type Nagashima, the most common PPK in Asia, is 1.2 per 10,000 and 3.1 per 10,000, respectively [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H2902861035"><span class="h1">CLASSIFICATION</span><span class="headingEndMark"> — </span>There is no unanimously accepted classification of hereditary PPK. Because of the high heterogeneity in clinical presentation, causative genetic defect, mode of inheritance, and presence or absence of associated features, the classification of PPKs can be based on a variety of criteria, including [<a href="#rid1">1,3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Presence or absence of other cutaneous and extracutaneous features – PPK may be isolated (nonsyndromic), associated with other genodermatoses (eg, ichthyosis, epidermolysis bullosa, ectodermal dysplasia), or associated with other organ involvement as a component of a complex syndrome (eg, Papillon-Lefèvre syndrome).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lesion morphology – Acral hyperkeratosis can be diffuse (involving the entire palmar and plantar surfaces) or limited to certain areas (focal, striate, punctate). PPK may be "transgrediens" (extending beyond the palms and soles) or "mutilating," due to the development of constrictive bands around the digits. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Histology – Cytolysis in granular layer keratinocytes may be present or absent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inheritance mode – PPK can be inherited in an autosomal dominant, autosomal recessive, or X-linked pattern. Mitochondrial inheritance has also been reported.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Genetic defect/disrupted molecular pathway [<a href="#rid8">8</a>].</p><p></p><p class="headingAnchor" id="H2565133168"><span class="h1">MOLECULAR PATHOGENESIS</span><span class="headingEndMark"> — </span>Mutations in genes encoding structural proteins supporting the granular layer of the epidermis cause hyperkeratotic diseases, including PPK. The PPK-causative genes include <em>KRT1</em> and <em>KRT9</em>, which encode major intermediate filaments of granular layer keratinocytes; <em>DSG1</em>, a major cell-cell adhesion molecule of desmosomes in the granular layer; <em>LOR</em>, a major component of cornified cell envelope expressed in granular layer cells; <em>SERPINB7 </em>and<em> SERPINA12</em>, serine proteinase inhibitors associated with degradation of DSG1 and CDSN that are expressed in granular layer cells; <em>AQP5</em>, a water channel protein expressed in granular layer cells; and <em>SLURP1</em>, a secreted protein associated with signal transduction that is expressed in granular layer cells. </p><p>Mutations in genes encoding proteins expressed in basal layer cells and associated with cell proliferation cause acanthosis and hyperkeratosis and result in PPK. They include <em>PTEN</em>, a tumor suppressor and a cell cycle regulator; <em>AAGAB</em>, a putative regulator of the turnover of epidermal growth factor receptor; and <em>RHBDF2</em>, a regulator of epidermal growth factor processing.</p><p class="headingAnchor" id="H1158889867"><span class="h1">DIFFUSE PALMOPLANTAR KERATODERMA</span><span class="headingEndMark"> — </span>Diffuse PPKs are characterized by epidermal thickening that involves the entire surface of palms and soles  (<a class="graphic graphic_table graphicRef120443" href="/z/d/graphic/120443.html" rel="external">table 1A</a>). The hyperkeratosis may show a sharp demarcation at the palmar or plantar border ("nontransgrediens") or may extend onto nonpalmar or plantar skin, such as the dorsal surfaces of the hands and feet, inner wrists, the Achilles tendon area, elbows, and knees ("transgrediens") [<a href="#rid3">3,5</a>]. Involvement beyond the palmar and plantar skin is observed in several diffuse PPKs, including mal de Meleda; acral keratoderma; and PPK types Nagashima, Bothnia, Gamborg-Nielsen, Greither, and Sybert [<a href="#rid9">9-17</a>]. </p><p class="headingAnchor" id="H3179226059"><span class="h2">Diffuse epidermolytic palmoplantar keratoderma (Vörner type, Unna-Thost type included)</span><span class="headingEndMark"> — </span>Diffuse epidermolytic PPK Vörner type (MIM #144200) is the most common PPK in White persons and is caused by a heterozygous pathogenic mutation in keratin gene <em>KRT1</em> or <em>KRT9</em> [<a href="#rid18">18</a>]. The mutations in<em> KRT1</em> or <em>KRT9</em> disrupt the formation of keratin intermediate filaments, which causes physical weakness of cytoskeletons. The vacuolar degeneration of cells (epidermolysis) is a result of physical cell damage caused by the weakness of cytoskeletons. </p><p>Because KRT9 is exclusively expressed in the keratinocytes of the palms and soles, the epidermolytic hyperkeratosis appears only on the palms and soles in <em>KRT9</em>-mutated patients. In contrast, KRT1 is expressed in the keratinocytes of the entire skin. Distinct heterozygous mutations of<em> KRT1</em> cause generalized epidermolytic hyperkeratosis with diffuse PPK. This condition is called epidermolytic ichthyosis (MIM #113800) and is considered allelic to Vörner disease. (See  <a class="medical medical_review" href="/z/d/html/97333.html" rel="external">"Keratinopathic ichthyoses", section on 'Epidermolytic ichthyosis'</a>.) </p><p>The mode of inheritance of diffuse epidermolytic PPK Vörner type is autosomal dominant. De novo mutations have been reported [<a href="#rid19">19</a>]. In autosomal dominant de novo mutations, both parents are unaffected with the disease, but each of the affected patients' future offspring have a 50 percent risk to inherit the disease. </p><p>PPK Vörner type becomes apparent at birth or early childhood and presents with diffuse, compact, yellowish hyperkeratosis limited to the palms and soles, with sharp demarcation at the volar border (nontransgrediens) and a surrounding erythematous margin  (<a class="graphic graphic_picture graphicRef120759 graphicRef121291" href="/z/d/graphic/120759.html" rel="external">picture 1A-B</a>). Hyperhidrosis is a frequent associated symptom. </p><p>The histologic examination of a skin biopsy shows hyperkeratosis and vacuolar degeneration of cells in the granular and spinous layers of the epidermis (epidermolytic hyperkeratosis). However, because the epidermolysis is induced by physical stimuli to the skin on a background weakness of keratin cytoskeleton, histologic examination may not consistently show epidermolysis.</p><p>Unna-Thost PPK (MIM #600962), which is also caused by mutations in <em>KRT1</em> and was formerly classified as nonepidermolytic diffuse PPK, is likely a misdiagnosis of PPK Vörner type, due to inconsistent presence of epidermolysis on histologic examination. The re-evaluation of skin histology from offspring of the original family described by Unna and Thost showed, in fact, epidermolytic hyperkeratosis [<a href="#rid20">20,21</a>]. </p><p>Moreover, the finding that mutations in descendants of the original families described by Vörner and by Unna and Thost are located on the coil-1A segment at the beginning of the central rod domain of <em>KRT9</em> further supports the theory that PPK Vörner type and PPK Unna-Thost type are not different types of PPK [<a href="#rid18">18,21</a>]. The designation "Unna-Thost" is thus misleading and should be avoided, while the term "PPK Vörner type" should be used for accurate description of epidermolytic hyperkeratosis. </p><p class="headingAnchor" id="H224261008"><span class="h2">Diffuse nonepidermolytic palmoplantar keratoderma</span></p><p class="headingAnchor" id="H246925538"><span class="h3">Diffuse palmoplantar keratoderma caused by <i>DSG1</i> mutations</span><span class="headingEndMark"> — </span>Autosomal dominant mutations in the desmoglein 1 gene (<em>DSG1</em>), which<em> </em>cause striate PPK type 1 (MIM #148700), have also been associated with a form of diffuse nonepidermolytic PPK [<a href="#rid22">22</a>]. (See <a class="local">'Striate palmoplantar keratoderma types 1, 2, and 3'</a> below.)</p><p>The histologic examination of a skin biopsy shows hyperkeratosis and acantholysis (disruption of desmosomal cell-cell adhesions caused by haploinsufficiency of desmoglein 1) in the granular layer of the epidermis [<a href="#rid22">22</a>].</p><p>Patients who inherit two <em>DSG1</em> mutations in a homozygous manner present with PPK and <strong>s</strong>evere dermatitis, multiple <strong>a</strong>llergies, and <strong>m</strong>etabolic wasting (SAM) syndrome<em> </em>[<a href="#rid23">23</a>]. This suggests that while heterozygous carriers of <em>DSG1</em> have limited PPK, complete loss of functional <em>DSG1</em> from both alleles results in a complex syndrome. (See  <a class="medical medical_review" href="/z/d/html/15512.html" rel="external">"Peeling skin syndromes", section on 'SAM syndrome'</a>.)</p><p class="headingAnchor" id="H522134402"><span class="h3">Mal de Meleda</span><span class="headingEndMark"> — </span>Mal de Meleda (keratosis palmoplantaris transgrediens, MIM #248300), first described on the Croatian island of Mljet (Meleda) in 1826, is an autosomal recessive PPK caused by biallelic mutations in <em>SLURP1</em> (encoding the secreted Ly6/uPAR related protein-1) [<a href="#rid24">24</a>]. In Europe and Mediterranean countries, the prevalence of the three most common mutations (c.82delT, p.R96X, and p.W15R) shows a marked geographic demarcation, suggesting a founder effect [<a href="#rid25">25</a>].</p><p>Mal de Meleda presents at birth or in early infancy with diffuse erythema and hyperkeratosis of the palms and soles that extends to the dorsal surface of feet and hands and gradually progress to involve the wrists and ankles  (<a class="graphic graphic_picture graphicRef120762 graphicRef120763" href="/z/d/graphic/120762.html" rel="external">picture 2A-B</a>). This distribution beyond the palmoplantar area is called "transgrediens." Circumferential hyperkeratosis of the fingers may result in constriction bands (pseudoainhum), spontaneous amputations, and flexion contractures. Hyperhidrosis, maceration, odor, and secondary fungal infection are common. Hyperkeratotic plaques may be present on the elbows and knees. Nails are also affected and may show thickening and koilonychia. </p><p class="headingAnchor" id="H2034528760"><span class="h3">Palmoplantar keratoderma Gamborg-Nielsen/Norrbotten type</span><span class="headingEndMark"> — </span>PPK Gamborg-Nielsen type (also called Norrbotten type, MIM #244850) was first described in Norrbotten, the northernmost county of Sweden. It shows a morphologic phenotype similar to mal de Meleda but with less severe hyperkeratosis and no nail deformities or distant keratosis, except for knuckle pads [<a href="#rid26">26</a>]. Genetic investigation revealed that Gamborg-Nielsen/Norrbotten PPK is an autosomal recessive PPK caused by distinct mutations of <em>SLURP1</em> [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H2355068811"><span class="h3">Palmoplantar keratoderma Nagashima type</span><span class="headingEndMark"> — </span>PPK Nagashima type (MIM #615598) is an autosomal recessive form of diffuse nonepidermolytic PPK caused by mutations in <em>SERPINB7</em>, which encodes a proteinase inhibitor expressed in the upper layers of the epidermis [<a href="#rid7">7</a>]. PPK Nagashima type is the most common PPK in Asian populations, with a widely spread founder mutation of <em>SERPINB7</em> (c.796C&gt;T). The prevalence of <em>SERPINB7</em> mutation carriers is estimated to be approximately 1 in 50 in Japanese and Chinese populations, with prevalence rates of PPK Nagashima type in Japan and China of 1.2 per 10,000 and 3.1 per 10,000, respectively [<a href="#rid7">7</a>].</p><p>PPK Nagashima type presents with a nonprogressive, mild hyperkeratosis with skin redness that extends to the dorsal surfaces of the hands and feet, inner wrists, ankles, and the Achilles tendon area  (<a class="graphic graphic_picture graphicRef120764 graphicRef120765" href="/z/d/graphic/120764.html" rel="external">picture 3A-B</a>) [<a href="#rid12">12,28</a>]. After exposure to water, the palms and soles show a characteristic whitish, spongy appearance. Hyperhidrosis, secondary fungal infection, and odor are common.</p><p class="headingAnchor" id="H2282228496"><span class="h3">Palmoplantar keratoderma with <i>SERPINA12</i> mutations</span><span class="headingEndMark"> — </span>Diffuse PPK with <em>SERPINA12</em> mutations is an autosomal recessive form of diffuse nonepidermolytic PPK caused by mutations in <em>SERPINA12</em>, which encodes vaspin (visceral adipose tissue-derived serine protease) inhibitor expressed in the upper layers of the epidermis and adipose tissues. Two patients of Muslim Arab descent and Jewish descent were identified in 2020 [<a href="#rid29">29</a>]. Six additional cases caused by novel variants in <em>SERPINA12</em> were subsequently identified in five unrelated families in China [<a href="#rid30">30</a>].</p><p>Clinical features resemble PPK Nagashima type, including erythematous, diffuse hyperkeratosis of the palms and soles with peripheral peeling, extending to the inner wrist area, the Achilles tendon area, and the anterior part of the leg.</p><p class="headingAnchor" id="H2226795793"><span class="h3">Palmoplantar keratoderma Bothnia type</span><span class="headingEndMark"> — </span>PPK Bothnia type (MIM #600231) is an autosomal dominant form of diffuse nonepidermolytic PPK caused by mutations in <em>AQP5</em> (encoding the water-channel protein aquaporin 5) [<a href="#rid31">31,32</a>]. PPK Bothnia type has a high prevalence of 0.3 to 0.55 percent in the two northernmost provinces of Sweden around the Gulf of Bothnia [<a href="#rid13">13</a>]. PPK Bothnia type resembles PPK Nagashima type, with mild transgrediens redness and hyperkeratosis and whitish changes upon water exposure  (<a class="graphic graphic_picture graphicRef120766 graphicRef120767" href="/z/d/graphic/120766.html" rel="external">picture 4A-B</a>) [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H1536616103"><span class="h3">Transgrediens et progrediens palmoplantar keratoderma (Greither disease)</span><span class="headingEndMark"> — </span>Transgrediens et progrediens PPK (Greither disease) is an autosomal dominant form of diffuse PPK caused by a <em>KRT1 </em>mutation [<a href="#rid33">33,34</a>]. It becomes apparent in infancy and is characterized by diffuse hyperkeratosis of the palms and soles, extending to the dorsal surface of the hands and feet and over the Achilles tendon, and a tendency to worsen with age. </p><p>Of note, mutations in <em>KRT1</em> are associated with widely heterogeneous clinical phenotypes. These include PPK Vörner type (MIM #144200), striate PPK, epidermolytic ichthyosis (MIM #113800), ichthyosis hystrix Curth-Macklin type (MIM #146590), and cyclic ichthyosis with epidermolytic hyperkeratosis (MIM #607602).</p><p class="headingAnchor" id="H4144904798"><span class="h1">FOCAL PALMOPLANTAR KERATODERMA</span><span class="headingEndMark"> — </span>Focal PPKs are characterized by painful, circumscribed hyperkeratosis resembling calluses on the weight-bearing areas of the soles  (<a class="graphic graphic_picture graphicRef120768" href="/z/d/graphic/120768.html" rel="external">picture 5</a>).</p><p class="headingAnchor" id="H1306815003"><span class="h2">Pachyonychia congenita</span><span class="headingEndMark"> — </span>Painful focal PPK with underlying blisters is a major manifestation of pachyonychia congenita  (<a class="graphic graphic_picture graphicRef117900" href="/z/d/graphic/117900.html" rel="external">picture 6</a>), an autosomal dominant disorder caused by heterozygous mutations in <em>KRT6A</em>, <em>KRT6B</em>, <em>KRT6C</em>, <em>KRT16</em>, or <em>KRT17</em> and characterized by hypertrophic nail dystrophy<em> </em>[<a href="#rid35">35</a>]. (See  <a class="medical medical_review" href="/z/d/html/15504.html" rel="external">"Pachyonychia congenita"</a>.)</p><p class="headingAnchor" id="H4111216912"><span class="h2">Focal nonepidermolytic palmoplantar keratoderma</span><span class="headingEndMark"> — </span>Distinct autosomal dominant mutations in <em>KRT6C</em> and <em>KRT16</em> cause focal nonepidermolytic PPK (MIM #615735 and #613000) [<a href="#rid36">36-40</a>]. Areas of keratoderma are present on the soles at sites of recurrent friction, with limited or even absent palm involvement or nail dystrophy.</p><p>Specific autosomal dominant mutations in <em>DSG1</em> (encoding desmoglein 1) cause phenotypically heterogeneous focal PPK type 1, with or without minimal changes in the nails and other ectodermal tissues [<a href="#rid22">22,41-45</a>]. </p><p>A missense heterozygous mutation in <em>TRPV3</em> (encoding a transient receptor potential cation channel, subfamily V, member 3) has been reported to cause focal nonepidermolytic PPK type 2 (MIM #616400) [<a href="#rid46">46</a>]. Several mutations in <em>TRPV3</em> have also been reported as the cause of Olmsted syndrome (MIM #614594), which shows mutilating diffuse PPKs and perioral hyperkeratotic plaques [<a href="#rid46">46,47</a>]. (See  <a class="medical medical_review" href="/z/d/html/15504.html" rel="external">"Pachyonychia congenita", section on 'Olmsted syndrome'</a>.)</p><p class="headingAnchor" id="H2015095852"><span class="h1">STRIATE PALMOPLANTAR KERATODERMA</span><span class="headingEndMark"> — </span>Striate PPK shows hyperkeratosis prominent in a linear pattern along the flexor aspects of the fingers  (<a class="graphic graphic_picture graphicRef120846" href="/z/d/graphic/120846.html" rel="external">picture 7</a>) and over pressure points on the soles.</p><p class="headingAnchor" id="H3203275059"><span class="h2">Striate palmoplantar keratoderma types 1, 2, and 3</span><span class="headingEndMark"> — </span>Striate PPK type 1 (MIM #148700), type 2 (MIM #612908), and type 3 (MIM #607654) are autosomal dominant PPKs caused by heterozygous mutations in <em>DSG1</em>, <em>DSP</em>, and <em>KRT1</em>, respectively [<a href="#rid42">42,48,49</a>]. </p><p>Patients with homozygous <em>DSG1</em> mutations via consanguineous parents present with an autosomal recessive condition with <strong>s</strong>evere dermatitis, multiple <strong>a</strong>llergies, and <strong>m</strong>etabolic wasting (SAM) syndrome (MIM #615508) [<a href="#rid23">23</a>]. Additional findings include congenital ichthyosiform erythroderma, focal and striate PPK, hypotrichosis, and hyper-immunoglobulin E (IgE).</p><p class="headingAnchor" id="H3949387"><span class="h2">Palmoplantar keratoderma and woolly hair</span><span class="headingEndMark"> — </span>PPK and woolly hair (MIM #616099) is a rare autosomal recessive PPK caused by homozygous mutation in the <em>KANK2</em> gene [<a href="#rid50">50</a>]. Members of two affected families presented with variable degree of striate PPK, leukonychia, sparse scalp and body hair, and, in some cases, woolly hair.</p><p class="headingAnchor" id="H3766098720"><span class="h1">PUNCTATE PALMOPLANTAR KERATODERMA</span><span class="headingEndMark"> — </span>Punctate PPK shows multiple tiny, hyperkeratotic papules on the palms and soles. The syndromic type includes Cowden syndrome 1, Cole disease, and PLACK (<strong>p</strong>eeling skin with <strong>l</strong>eukonychia, <strong>a</strong>cral punctate keratoses, <strong>c</strong>heilitis, and <strong>k</strong>nuckle pads) syndrome. (See <a class="local">'Syndromic palmoplantar keratoderma'</a> below.)</p><p class="headingAnchor" id="H2858687847"><span class="h2">Punctate palmoplantar keratoderma type 1</span><span class="headingEndMark"> — </span>Punctate PPK type 1A, also called PPK type Buschke-Fischer-Brauer (MIM #148600), is an autosomal dominant PPK caused by heterozygous mutations in <em>AAGAB</em> (encoding alpha- and gamma-adaptin-binding protein p34) [<a href="#rid51">51-54</a>]. It appears during late childhood to adolescence, with multiple tiny, punctate keratoses on the palms and soles that increase in number and size with age  (<a class="graphic graphic_picture graphicRef120848" href="/z/d/graphic/120848.html" rel="external">picture 8</a>). </p><p>A heterozygous mutation in <em>COL14A1</em> (encoding collagen 14) has been identified in a large Chinese family with punctate PPK type 1B [<a href="#rid54">54</a>].</p><p class="headingAnchor" id="H1386686649"><span class="h2">Punctate palmoplantar keratoderma type 2</span><span class="headingEndMark"> — </span>Punctate PPK type 2, also called porokeratosis punctate palmaris et plantaris, is probably an autosomal dominant disorder that presents with numerous tiny, keratotic spines on the palms and soles. Histologic studies showed distinct epidermal depressions containing cornoid lamellae [<a href="#rid55">55,56</a>]. The causative gene is unknown.</p><p class="headingAnchor" id="H3562038139"><span class="h2">Punctate palmoplantar keratoderma type 3 (acrokeratoelastoidosis)</span><span class="headingEndMark"> — </span>Punctate PPK type 3, also called acrokeratoelastoidosis (MIM #101850), is an autosomal dominant disorder characterized by papular, yellowish or brown lesions with a hyperkeratotic surface on the lateral and dorsal aspects of palms and soles  (<a class="graphic graphic_picture graphicRef120174 graphicRef126447 graphicRef126449 graphicRef126448" href="/z/d/graphic/120174.html" rel="external">picture 9A-D</a>) [<a href="#rid57">57</a>]. Histologic findings include hyperkeratosis, mild acanthosis, and degeneration of the elastic fibers. The causative gene is unknown.</p><p class="headingAnchor" id="H4272090590"><span class="h1">SYNDROMIC PALMOPLANTAR KERATODERMA</span><span class="headingEndMark"> — </span>Syndromic PPKs include a large number of conditions characterized by PPK and extracutaneous involvement [<a href="#rid4">4</a>]. PPK may also be a feature of certain genodermatoses, including some forms of ichthyosis and ectodermal dysplasias and some subtypes of epidermolysis bullosa.</p><p class="headingAnchor" id="H2961211154"><span class="h2">Palmoplantar keratodermas with deafness</span><span class="headingEndMark"> — </span>Heterozygous mutations in <em>GJB2</em> (which encodes the gap junction protein connexin 26) cause a number of autosomal dominant disorders characterized by diffuse PPK with hearing impairment and various associated extracutaneous features [<a href="#rid1">1,2,4,58,59</a>]. These include classic Vohwinkel syndrome, PPK with neurosensory deafness, keratitis-ichthyosis-deafness (KID) syndrome, Bart-Pumphrey syndrome, and hystrix-like ichthyosis with deafness (HID) syndrome. Allelic mutations in <em>GJB2</em> are also known to cause autosomal dominant and autosomal recessive forms of nonsyndromic congenital hearing loss. (See  <a class="medical medical_review" href="/z/d/html/6308.html" rel="external">"Hearing loss in children: Etiology"</a>.)</p><p>Another rare PPK associated with deafness is caused by mitochondrial mutations.</p><p class="headingAnchor" id="H133696024"><span class="h3">Vohwinkel syndrome</span><span class="headingEndMark"> — </span>Classic Vohwinkel syndrome (MIM #124500), also called mutilating PPK, is a rare autosomal dominant condition caused by mutations in <em>GJB2</em>. It is characterized by congenital deafness or hearing impairment; diffuse PPK with a characteristic honeycomb pattern  (<a class="graphic graphic_picture graphicRef120206" href="/z/d/graphic/120206.html" rel="external">picture 10</a>); starfish-shaped, hyperkeratotic plaques on knuckles  (<a class="graphic graphic_picture graphicRef120197" href="/z/d/graphic/120197.html" rel="external">picture 11</a>); and mutilating digital constriction rings around fingers and toes (pseudoainhum) that result in spontaneous autoamputation  (<a class="graphic graphic_picture graphicRef120207" href="/z/d/graphic/120207.html" rel="external">picture 12</a>) [<a href="#rid60">60</a>].</p><p class="headingAnchor" id="H1960458841"><span class="h3">Palmoplantar keratoderma with deafness</span><span class="headingEndMark"> — </span>PPK with deafness (MIM #148350) is an autosomal dominant condition caused by mutations in <em>GJB2 </em>and characterized by mild to severe neurosensory hearing impairment and diffuse or focal palmoplantar hyperkeratosis [<a href="#rid59">59,61,62</a>]. </p><p class="headingAnchor" id="H2711674981"><span class="h3">KID syndrome</span><span class="headingEndMark"> — </span>Keratitis-ichthyosis-deafness (KID) syndrome (MIM #148210) is a rare disease caused by mutations in <em>GJB2</em>. It presents in infants with striking ichthyosiform erythroderma  (<a class="graphic graphic_picture graphicRef90662" href="/z/d/graphic/90662.html" rel="external">picture 13</a>); later, patients may develop PPK  (<a class="graphic graphic_picture graphicRef120850" href="/z/d/graphic/120850.html" rel="external">picture 14</a>), recurrent fungal infections, characteristic corneal redness, alopecia, nail dystrophy, and increased risk of squamous cell carcinoma [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/z/d/html/15465.html" rel="external">"Overview and classification of the inherited ichthyoses", section on 'KID syndrome'</a>.)</p><p class="headingAnchor" id="H4170195781"><span class="h3">HID syndrome</span><span class="headingEndMark"> — </span>Hystrix-like ichthyosis with deafness (HID) syndrome (MIM #602540) is an exceedingly rare autosomal dominant disorder that shares some features with KID syndrome and is caused by the same mutation in <em>GJB2</em> [<a href="#rid58">58</a>]. </p><p class="headingAnchor" id="H939493647"><span class="h3">Bart-Pumphrey syndrome</span><span class="headingEndMark"> — </span>Bart-Pumphrey syndrome, also called knuckle pads, leukonychia, and sensorineural deafness (MIM #149200), is an autosomal dominant disorder caused by mutations in <em>GJB2</em> and characterized by diffuse, focal, or punctate PPK appearing in early childhood and congenital deafness [<a href="#rid2">2,63</a>]. Knuckle pads are nodular or plaque-like skin thickenings overlying the metacarpophalangeal and proximal interphalangeal joints  (<a class="graphic graphic_picture graphicRef120422" href="/z/d/graphic/120422.html" rel="external">picture 15</a>) [<a href="#rid64">64</a>].</p><p class="headingAnchor" id="H2396852362"><span class="h3">Mitochondrial palmoplantar keratoderma with deafness</span><span class="headingEndMark"> — </span>The <em>A7445G</em> mutation in mitochondrial DNA has been associated with nonepidermolytic PPK with sensorineural hearing loss, as well as with nonsyndromic deafness [<a href="#rid65">65,66</a>]. This type of PPK is maternally inherited with variable penetrance and expressivity.</p><p class="headingAnchor" id="H741837600"><span class="h2">Palmoplantar keratoderma with ichthyosis and normal hearing</span></p><p class="headingAnchor" id="H3138592000"><span class="h3">Vohwinkel syndrome with ichthyosis</span><span class="headingEndMark"> — </span>Vohwinkel syndrome with ichthyosis (MIM #604117), also called loricrin keratoderma, is an autosomal dominant disorder caused by mutations in <em>LOR</em>, encoding loricrin (a major protein of the cornified envelope). A severe form shows mutilating PPK, as in classic Vohwinkel syndrome, and generalized ichthyosis; a mild type shows only dry skin and PPK [<a href="#rid2">2,67</a>]. There is no associated hearing loss. </p><p class="headingAnchor" id="H1268666244"><span class="h3">KLICK syndrome</span><span class="headingEndMark"> — </span>Keratosis linearis with ichthyosis congenita and sclerosing keratoderma (KLICK) syndrome (MIM #601952) is a very rare autosomal recessive disorder caused by mutations in proteasome maturation protein gene (<em>POMP</em>) [<a href="#rid68">68</a>]. It shows diffuse, transgressive PPK; linear, hyperkeratotic plaques around the wrists and in the antecubital and popliteal folds; constricting bands around the fingers; flexural deformities; and congenital ichthyosis [<a href="#rid69">69</a>].</p><p class="headingAnchor" id="H1506175655"><span class="h2">Palmoplantar keratoderma with periodontitis</span></p><p class="headingAnchor" id="H4053091272"><span class="h3">Papillon-Lefèvre syndrome</span><span class="headingEndMark"> — </span>Papillon-Lefèvre syndrome (MIM #245000) is a rare autosomal recessive disorder caused by mutations in <em>CTSC</em> (encoding cathepsin C) [<a href="#rid70">70</a>]. It shows diffuse PPK in a transgrediens pattern  (<a class="graphic graphic_picture graphicRef120374" href="/z/d/graphic/120374.html" rel="external">picture 16</a>), early-onset periodontitis leading to premature loss of both milk and permanent teeth  (<a class="graphic graphic_picture graphicRef66117" href="/z/d/graphic/66117.html" rel="external">picture 17</a>), and recurrent cutaneous and systemic infections [<a href="#rid71">71-73</a>]. (See  <a class="medical medical_review" href="/z/d/html/6281.html" rel="external">"Periodontal disease in children: Associated systemic conditions", section on 'Papillon-Lefèvre syndrome'</a>.)</p><p class="headingAnchor" id="H558832842"><span class="h3">Haim-Munk syndrome</span><span class="headingEndMark"> — </span>Haim-Munk syndrome (MIM #245010) is an autosomal recessive disorder caused by mutations in <em>CTSC</em> and, thus, allelic to Papillon-Lefèvre syndrome [<a href="#rid74">74</a>]. Haim-Munk syndrome has been described only among descendants of a religious isolate originally from Cochin, India, and is characterized by PPK, severe periodontitis, arachnodactyly, acroosteolysis, pes planus, and finger deformities.</p><p class="headingAnchor" id="H3294855265"><span class="h2">Palmoplantar keratoderma associated with cardiomyopathy and woolly hair</span></p><p class="headingAnchor" id="H1932013492"><span class="h3">Carvajal syndrome</span><span class="headingEndMark"> — </span>Carvajal syndrome, also called PPK with left ventricular cardiomyopathy and woolly hair (MIM #605676), is an autosomal recessive disorder caused by mutations in <em>DSP</em>, encoding desmoplakin (an intracellular scaffold protein of desmosome) [<a href="#rid75">75,76</a>]. It shows striate PPK, cardiomyopathy, and woolly hair [<a href="#rid77">77</a>]. </p><p>An autosomal dominant variant of Carvajal syndrome is associated with tooth agenesis (MIM #615821) [<a href="#rid78">78,79</a>]. (See  <a class="medical medical_review" href="/z/d/html/4912.html" rel="external">"Inherited syndromes associated with cardiac disease", section on 'Naxos disease and Carvajal syndrome'</a>.)</p><p class="headingAnchor" id="H1745286516"><span class="h3">Naxos disease</span><span class="headingEndMark"> — </span>Naxos disease (MIM #601214) is an autosomal recessive disorder caused by mutations in <em>JUP</em>, encoding plakoglobin (an intracellular scaffold protein of desmosome) [<a href="#rid80">80</a>]. It shows diffuse PPK, arrhythmogenic right ventricular dysplasia, and woolly hair. (See  <a class="medical medical_review" href="/z/d/html/4912.html" rel="external">"Inherited syndromes associated with cardiac disease", section on 'Naxos disease and Carvajal syndrome'</a>.) </p><p class="headingAnchor" id="H2548628659"><span class="h3">Arrhythmogenic right ventricular dysplasia with mild palmoplantar keratoderma</span><span class="headingEndMark"> — </span>Arrhythmogenic right ventricular dysplasia associated with mild PPK and woolly hair (MIM #610476) due to homozygous mutations in <em>DSC2</em>, encoding desmocollin 2 (an intracellular scaffold protein of desmosome), has also been reported [<a href="#rid81">81</a>].</p><p class="headingAnchor" id="H4091397151"><span class="h2">Palmoplantar keratoderma associated with ectodermal dysplasia</span></p><p class="headingAnchor" id="H3687765691"><span class="h3">Clouston syndrome</span><span class="headingEndMark"> — </span>Clouston syndrome (MIM #129500) is an autosomal dominant disorder caused by mutations in <em>GJB6</em>, encoding connexin 30 (a gap junction protein) [<a href="#rid82">82</a>]. It shows moderate to severe diffuse PPK  (<a class="graphic graphic_picture graphicRef117170" href="/z/d/graphic/117170.html" rel="external">picture 18</a>) with nail dystrophy  (<a class="graphic graphic_picture graphicRef117169" href="/z/d/graphic/117169.html" rel="external">picture 19</a>) and hair abnormalities. In contrast with KID syndrome due to <em>GJB2</em> mutations, patients with Clouston syndrome do not have neurosensory deafness. (See  <a class="medical medical_review" href="/z/d/html/110146.html" rel="external">"Ectodermal dysplasias", section on 'Ectodermal dysplasia 2, Clouston type'</a>.)</p><p class="headingAnchor" id="H2514952475"><span class="h3">Naegeli-Franceschetti-Jadassohn syndrome</span><span class="headingEndMark"> — </span>Naegeli-Franceschetti-Jadassohn syndrome (MIM #161000) is an autosomal dominant disorder caused by mutations in <em>KRT14</em> [<a href="#rid83">83</a>]. It shows diffuse PPK, nail dystrophies, anhidrosis, dental defects, and reticulate hyperpigmentation  (<a class="graphic graphic_picture graphicRef111989" href="/z/d/graphic/111989.html" rel="external">picture 20</a>) [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/z/d/html/111807.html" rel="external">"Congenital and inherited hyperpigmentation disorders", section on 'Naegeli-Franceschetti-Jadassohn syndrome'</a>.)</p><p class="headingAnchor" id="H3079459662"><span class="h3">Odonto-onycho-dermal dysplasia</span><span class="headingEndMark"> — </span>Odonto-onycho-dermal dysplasia (MIM #257980) is an autosomal recessive disorder caused by mutations in <em>WNT10A </em>[<a href="#rid84">84,85</a>]. The <em>WNT</em> gene family is a group of related genes encoding signaling molecules involved in the differentiation of various cell lineages through the canonical Wnt/beta-catenin signaling pathway. Odonto-onycho-dermal dysplasia is characterized by diffuse PPK, hyperhidrosis, hypodontia, smooth tongue, hypotrichosis, and dystrophic nails.</p><p class="headingAnchor" id="H2174369750"><span class="h3">Schöpf-Schulz-Passarge syndrome</span><span class="headingEndMark"> — </span>Schöpf-Schulz-Passarge syndrome (MIM #224750) is an autosomal recessive disorder caused by mutations in <em>WNT10A</em> [<a href="#rid86">86</a>]. It resembles odonto-onycho-dermal dysplasia but is complicated by eyelid cysts (hidrocystomas) and an increased risk of skin tumors [<a href="#rid2">2,47</a>].</p><p class="headingAnchor" id="H1510249117"><span class="h3">Skin fragility syndromes</span><span class="headingEndMark"> — </span>Ectodermal dysplasia/skin fragility syndrome and skin fragility/woolly hair syndrome are rare autosomal recessive disorders caused by mutations in <em>PKP1</em>, encoding plakophilin 1<em> </em>(MIM #604536), or in <em>DSP</em>, encoding desmoplakin (MIM #607655), respectively [<a href="#rid87">87-89</a>]. Although these disorders primarily cause skin fragility, PPK is thought to be a compensatory response. These skin fragility diseases are considered variants of suprabasal epidermolysis bullosa simplex and are characterized by a variable constellation of clinical findings, including generalized skin fragility, diffuse PPK with painful fissures, hypotrichosis or woolly hair, and growth retardation  (<a class="graphic graphic_table graphicRef77709" href="/z/d/graphic/77709.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/15449.html" rel="external">"Epidermolysis bullosa: Epidemiology, pathogenesis, classification, and clinical features", section on 'Epidermolysis bullosa simplex'</a>.)</p><p class="headingAnchor" id="H41883132"><span class="h2">Palmoplantar keratoderma associated with peeling skin/blistering and leukonychia</span></p><p class="headingAnchor" id="H2469311026"><span class="h3">PLACK syndrome</span><span class="headingEndMark"> — </span>PLACK (<strong>p</strong>eeling skin with <strong>l</strong>eukonychia, <strong>a</strong>cral punctate keratoses, <strong>c</strong>heilitis, and <strong>k</strong>nuckle pads; MIM #616295) syndrome is a rare autosomal recessive disorder caused by mutations in <em>CAST</em>. It shows peeling skin, leukonychia, acral punctate keratoses, cheilitis, and knuckle pads [<a href="#rid90">90</a>]. (See  <a class="medical medical_review" href="/z/d/html/15512.html" rel="external">"Peeling skin syndromes", section on 'PLACK syndrome'</a>.)</p><p class="headingAnchor" id="H3379026500"><span class="h2">Palmoplantar keratoderma associated with guttate hypopigmentation</span></p><p class="headingAnchor" id="H1494377651"><span class="h3">Cole disease</span><span class="headingEndMark"> — </span>Cole disease (MIM #615522) is a rare autosomal dominant disorder caused by heterozygous mutations in <em>ENPP1</em> [<a href="#rid91">91,92</a>]. It shows congenital or early-onset, punctate PPK associated with irregularly shaped, guttate hypopigmentation distributed over the arms and legs but not on the trunk or acral regions. Some patients exhibit calcinosis cutis or early-onset, calcific tendinopathy.</p><p class="headingAnchor" id="H3987876531"><span class="h2">Palmoplantar keratoderma associated with increased risk of cancer</span></p><p class="headingAnchor" id="H1112930634"><span class="h3">Tylosis with esophageal cancer</span><span class="headingEndMark"> — </span>Tylosis with esophageal cancer (MIM #148500), also known as Howel-Evans syndrome, is an extremely rare autosomal dominant disorder caused by mutations in <em>RHBDF2</em>, the protein product of which interacts with ADAM metallopeptidase domain 17 (ADAM17, also called TACE) and regulates epidermal growth factor processing [<a href="#rid93">93</a>]. It is characterized by focal PPK, increased risk of esophageal cancer, and oral precursor lesions, such as leukoplakia [<a href="#rid93">93,94</a>]. (See  <a class="medical medical_review" href="/z/d/html/2274.html" rel="external">"Epidemiology and pathobiology of esophageal cancer", section on 'Tylosis'</a>.)</p><p>In the absence of molecular diagnosis, use of a targeted family history is useful to detect the presence of oral and/or esophageal cancer-affected family members. Those patients with tylosis and a personal or family history of esophageal or oral cancer warrant further screening.</p><p class="headingAnchor" id="H4038058832"><span class="h3">Huriez syndrome</span><span class="headingEndMark"> — </span>Huriez syndrome, also known as sclerotylosis, is a very rare autosomal dominant genodermatosis characterized by diffuse and transgrediens PPK, scleroatrophy of the distal extremities, hypoplastic nails, and increased risk of developing aggressive squamous cell carcinoma in the affected areas [<a href="#rid2">2,95</a>]. Based on whole genome sequencing studies, it has been proposed that Huriez syndrome is caused by haploinsufficiency of <em>SMARCAD1</em>, encoding human helicase 1 (involved in high-fidelity homologous recombination repair of DNA double-strand breaks) [<a href="#rid96">96</a>].</p><p class="headingAnchor" id="H489453749"><span class="h3">Cowden syndrome 1</span><span class="headingEndMark"> — </span>Cowden syndrome 1 (MIM #158350) is an autosomal dominant disorder caused by mutations in <em>PTEN</em> and characterized by overgrowth, especially hamartomas that can involve any organ and an increased risk of internal cancers [<a href="#rid97">97</a>]. Mucocutaneous lesions include punctate acral keratoses  (<a class="graphic graphic_picture graphicRef120851" href="/z/d/graphic/120851.html" rel="external">picture 21</a>), facial trichilemmomas, papillomatous oral lesions, lipomas, hemangiomas, and pigmented, speckled macules of the glans penis in males [<a href="#rid98">98</a>]. (See  <a class="medical medical_review" href="/z/d/html/16543.html" rel="external">"PTEN hamartoma tumor syndromes, including Cowden syndrome"</a>.)</p><p class="headingAnchor" id="H3360066010"><span class="h3">Olmsted syndrome</span><span class="headingEndMark"> — </span>Olmsted syndrome is a rare keratinizing disorder characterized by the combination of bilateral mutilating transgrediens PPK and periorificial hyperkeratotic plaques with severe pruritus [<a href="#rid99">99</a>]. Associated features include diffuse alopecia, nail dystrophy, oral leukokeratosis, corneal dystrophy, recurrent infections, and susceptibility to develop squamous cell carcinomas in the keratotic areas.</p><p>Olmsted syndrome is inherited in an autosomal dominant, autosomal recessive, or X-linked mode. Autosomal dominant Olmsted syndrome (MIM #614594) is caused by mutations in <em>TRPV3 </em>[<a href="#rid47">47</a>], and X-linked Olmsted syndrome (MIM #300918) is caused by a mutation in <em>MBTPS2 </em>[<a href="#rid2">2</a>]. Olmsted syndrome shows diffuse and mutilating PPK and perioral hyperkeratotic plaques with severe pruritus. Diffuse alopecia, constriction of the digits, and onychodystrophy have been reported [<a href="#rid2">2,78</a>].</p><p class="headingAnchor" id="H445131807"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of specific inherited PPKs may be challenging due to considerable clinical and genetic heterogeneity of this group of diseases. A careful physical examination, including the entire skin surface, mucous membranes, nails, eyes, and hair, and a detailed personal and family history, especially for the presence or absence of esophageal and oral cancers, are the first step in the diagnostic approach [<a href="#rid2">2,4,5</a>]. A multidisciplinary approach may be needed if extracutaneous abnormalities are detected or suspected on physical examination. Histopathologic and, if available, ultrastructural examination of a skin biopsy can be of value in supporting the clinical diagnosis and directing genetic testing.</p><p>The approach to the diagnosis of PPK based on the clinical phenotype is illustrated in the algorithm  (<a class="graphic graphic_algorithm graphicRef131627" href="/z/d/graphic/131627.html" rel="external">algorithm 1</a>) [<a href="#rid100">100</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Physical</strong> <strong>examination</strong> – Relevant clinical features that may orient the diagnosis include the distribution and morphology of lesions and associated signs and symptoms:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Diffuse versus focal, striate, or punctate PPK</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Presence or absence of transgrediens hyperkeratosis (affected skin area extends or does not extend onto the dorsal surfaces of the hands and feet, inner wrists, and the Achilles tendon area)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Aspect of hyperkeratosis (waxy, compact with fissures, with associated erythema and desquamation)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Changes upon water exposure</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Presence of acral, sclerotic changes or digit constrictions</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Presence of palmoplantar hyperhidrosis</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Significant pain</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Presence of additional cutaneous findings (erythroderma, generalized ichthyosis, skin fragility)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nail, hair, mucosal, and dental abnormalities</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Major extracutaneous findings (hearing loss, cardiac manifestations, internal malignancies, ocular keratitis)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>History</strong> – Onset in infancy or early childhood, a positive family history, or parental consanguinity support the diagnosis of inherited PPK.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Histopathology</strong> – Routine histopathologic examination may show, in addition to unspecific findings such as hyperkeratosis and acanthosis, the presence of epidermolysis (cytolysis of granular layer keratinocytes), which helps in distinguishing epidermolytic from nonepidermolytic PPK. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic testing</strong> – The identification of the causative mutation in candidate genes allows a precise diagnosis in most cases  (<a class="graphic graphic_algorithm graphicRef131627" href="/z/d/graphic/131627.html" rel="external">algorithm 1</a>). Founder mutations or hot spot mutations are known in several PPKs. In such cases, Sanger sequencing to check the candidate mutations is first recommended. PPK caused by widespread founder mutations includes mal de Meleda in the Adriatic region (p.W15R of <em>SLURP1</em>) and PPK type Nagashima in Asian countries (p.R266*). Hot spot mutations at p.163Arg in <em>KRT9</em> cause PPK type Vörner.</p><p></p><p class="bulletIndent1">For forms of PPK that defy a clinical diagnosis based on the clinical presentation, exome sequencing is a valuable technique to identify disease-causative mutations. One strategy is to request a panel type blood test that includes sequencing and deletion/duplication testing of candidate genes well known to cause PPK, if available. If standard panel testing does not reveal causative mutation(s), then whole exome sequencing offers a next-step option when available.</p><p></p><p class="headingAnchor" id="H1144627992"><span class="h1">DIFFERENTIAL DIAGNOSIS</span></p><p class="headingAnchor" id="H1607234735"><span class="h2">Acquired palmoplantar keratoderma</span><span class="headingEndMark"> — </span>PPK may be a feature of a broad range of acquired skin disorders and is more commonly seen in clinical practice than hereditary PPK. Underlying causes include [<a href="#rid101">101</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Contact dermatitis  (<a class="graphic graphic_picture graphicRef120852" href="/z/d/graphic/120852.html" rel="external">picture 22</a>) and chronic hand eczema  (<a class="graphic graphic_picture graphicRef95750" href="/z/d/graphic/95750.html" rel="external">picture 23</a>). (See  <a class="medical medical_review" href="/z/d/html/13658.html" rel="external">"Chronic hand eczema"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Psoriasis  (<a class="graphic graphic_picture graphicRef93909 graphicRef120853" href="/z/d/graphic/93909.html" rel="external">picture 24A-B</a>). (See  <a class="medical medical_review" href="/z/d/html/5664.html" rel="external">"Psoriasis: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pityriasis rubra pilaris  (<a class="graphic graphic_picture graphicRef87825 graphicRef87793" href="/z/d/graphic/87825.html" rel="external">picture 25A-B</a>). (See  <a class="medical medical_review" href="/z/d/html/15283.html" rel="external">"Pityriasis rubra pilaris: Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Keratoderma climactericum – Keratoderma climactericum (Haxthausen's disease) is an acquired keratoderma with painful fissuring described in some postmenopausal women [<a href="#rid102">102,103</a>]. It develops initially on the soles at the pressure points and then becomes confluent. Later, it may extend to the palms. The cause is unknown. Associated factors include obesity and hypertension. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Exposure to certain chemicals, such as arsenic and chlorinated hydrocarbons  (<a class="graphic graphic_picture graphicRef120222" href="/z/d/graphic/120222.html" rel="external">picture 26</a>). (See  <a class="medical medical_review" href="/z/d/html/2778.html" rel="external">"Arsenic exposure and chronic poisoning", section on 'Dermatologic'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Drugs – An example is hand-foot skin reaction in cancer patients treated with multitargeted tyrosine kinase inhibitors. (See  <a class="medical medical_review" href="/z/d/html/103060.html" rel="external">"Hand-foot skin reaction induced by multitargeted tyrosine kinase inhibitors"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infections and infestations – Fungal infection, especially from <em>Trichophyton rubrum</em>, may cause hyperkeratosis of palms and/or soles that is typically unilateral but may be symmetric.  (<a class="graphic graphic_picture graphicRef120464" href="/z/d/graphic/120464.html" rel="external">picture 27</a>). Crusted scabies (Norwegian scabies) can be associated with massive hyperkeratosis of palms and soles  (<a class="graphic graphic_picture graphicRef120466" href="/z/d/graphic/120466.html" rel="external">picture 28</a>). (See  <a class="medical medical_review" href="/z/d/html/4038.html" rel="external">"Scabies: Epidemiology, clinical features, and diagnosis", section on 'Crusted scabies'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Systemic disease, such as myxedema or chronic lymphedema. (See  <a class="medical medical_review" href="/z/d/html/7846.html" rel="external">"Clinical manifestations of hypothyroidism", section on 'Skin'</a> and  <a class="medical medical_review" href="/z/d/html/755.html" rel="external">"Clinical features and diagnosis of peripheral lymphedema"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mycosis fungoides – Hyperkeratosis of palms and soles may occur in association with, or even precede, mycosis fungoides. Rarely, it can be the only manifestation of the disease. (See  <a class="medical medical_review" href="/z/d/html/15872.html" rel="external">"Variants of mycosis fungoides", section on 'Mycosis fungoides palmaris et plantaris'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Internal malignancies – PPK may occur as a paraneoplastic manifestation in a variety of internal cancers, including lung, esophageal, bladder, breast, and colon cancer. (See  <a class="medical medical_review" href="/z/d/html/7606.html" rel="external">"Cutaneous manifestations of internal malignancy", section on 'Hyperkeratotic and proliferative dermatoses'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bullous pemphigoid – Transient PPK has been reported in some patients with bullous pemphigoid [<a href="#rid104">104,105</a>]. (See  <a class="medical medical_review" href="/z/d/html/16176.html" rel="external">"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid"</a>.)</p><p></p><p>Acquired PPKs usually do not develop during infancy, and there is no associated family history. However, it should be kept in mind that several hereditary PPKs do <strong>not</strong> manifest in early childhood, and family history may be negative in patients affected by hereditary PPK due to de novo autosomal dominant mutations and in those with autosomal recessive forms who have unaffected carrier parents.</p><p>In contrast with hereditary PPK, usually showing a left-right symmetric distribution of skin lesions, acquired PPK tends to show left-right asymmetric involvement. Acquired PPK usually improves and may resolve with the treatment of the underlying condition. Examples include PPK due to contact dermatitis, which may respond to topical corticosteroids and avoidance of the offending allergen, and PPK associated with psoriasis, which may improve with topical psoralen plus ultraviolet A (PUVA) treatment of the soles and palms. (See  <a class="medical medical_review" href="/z/d/html/13749.html" rel="external">"Psoralen plus ultraviolet A (PUVA) photochemotherapy", section on 'Topical PUVA'</a>.)</p><p class="headingAnchor" id="H3595652389"><span class="h2">Other genodermatoses associated with palmoplantar keratoderma</span><span class="headingEndMark"> — </span>PPK can be a feature in a number of genodermatoses, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Darier disease  (<a class="graphic graphic_picture graphicRef86185" href="/z/d/graphic/86185.html" rel="external">picture 29</a>) (see  <a class="medical medical_review" href="/z/d/html/15462.html" rel="external">"Darier disease"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acrokeratosis verruciformis of Hopf  (<a class="graphic graphic_picture graphicRef86093" href="/z/d/graphic/86093.html" rel="external">picture 30</a>) (see  <a class="medical medical_review" href="/z/d/html/15462.html" rel="external">"Darier disease", section on 'Acrokeratosis verruciformis of Hopf'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Epidermodysplasia verruciformis  (<a class="graphic graphic_picture graphicRef102317" href="/z/d/graphic/102317.html" rel="external">picture 31</a>) (see  <a class="medical medical_review" href="/z/d/html/15509.html" rel="external">"Epidermodysplasia verruciformis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Epidermolysis bullosa simplex  (<a class="graphic graphic_picture graphicRef120855 graphicRef120856" href="/z/d/graphic/120855.html" rel="external">picture 32A-B</a>) (see  <a class="medical medical_review" href="/z/d/html/15449.html" rel="external">"Epidermolysis bullosa: Epidemiology, pathogenesis, classification, and clinical features"</a>)</p><p></p><p class="headingAnchor" id="H1849911233"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Treatment of hereditary PPK is difficult. Major goals of treatment are softening the hyperkeratotic skin, reducing its thickness and making it less noticeable, and controlling discomfort and pain. However, in most cases, treatment results in limited and temporary improvement. Patients with syndromic PPK require an individualized, multidisciplinary approach based on the type and severity of associated clinical signs and symptoms.</p><p>Because of its rarity and clinical heterogeneity, there is a lack of high-quality clinical studies on PPK. The approach to the management of these patients is based on clinical experience and very limited evidence from case reports and small case series.</p><p class="headingAnchor" id="H157660787"><span class="h2">General measures</span><span class="headingEndMark"> — </span>Patients with certain types of PPK will benefit from daily to weekly bath soaks followed by gentle mechanical scale removal with tools that are chosen according to patient preference. Examples of useful tools include a pumice stone, a synthetic polyurethane pumice bar (which is softer), or a callus file. Professional foot and hand care may be appropriate for some patients. Frequent and liberal use of emollients is advisable. </p><p>Physical therapy may useful if unreducible contractures of the fingers or palms are present.</p><p>Secondary bacterial and fungal infections, often presenting with worsening of pain, maceration, and odor, should be treated with appropriate topical or systemic antimicrobial therapy. Patients with mal de Meleda, PPK Nagashima type, and keratitis-ichthyosis-deafness (KID) syndrome are especially predisposed to fungal infection and benefit from antifungal treatment.</p><p class="headingAnchor" id="H3807639165"><span class="h2">Pharmacologic therapies</span><span class="headingEndMark"> — </span>Pharmacologic therapies that can be used for the treatment of PPK include topical keratolytics, topical retinoids, and systemic retinoids. None of these treatments provide a long-term benefit, and recurrence is common when they are discontinued:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Keratolytics</strong> – Topical creams or ointments containing urea, lactic acid, salicylic acid, or propylene glycol at various concentrations and in various combinations are used to soften the hyperkeratotic stratum corneum. Concentrations of urea greater than 20% and up to 40% may be required for thick hyperkeratosis. Patients with unsatisfactory response to single keratolytics may benefit from using ointments containing a combination of keratolytics, such as 5% lactic acid with 10% urea or 2% salicylic acid with 20% urea. Keratolytic preparations should be used with caution in children, due to the risk of systemic absorption. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topical retinoids</strong> – Topical retinoids, such <a class="drug drug_general" data-topicid="9665" href="/z/d/drug information/9665.html" rel="external">tazarotene</a> (0.05% or 0.1% cream) or <a class="drug drug_general" data-topicid="10014" href="/z/d/drug information/10014.html" rel="external">topical tretinoin</a> (0.025% to 0.1% cream), may be a treatment option for mild cases of PPK. They should be trialed gradually (eg, applied once per week starting with a small area of the hand or foot) to be sure irritation is not excessive. The treatment area and frequency of application can then be increased as tolerated. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Systemic retinoids</strong> – In patients with thick keratodermas or punctate keratodermas that are causing debilitating pain with walking or hand contractures that limit dexterity or activities of daily living, a trial of oral retinoids may be attempted [<a href="#rid106">106-109</a>]. Systemic retinoids include <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a>, <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a>, etretinate, and <a class="drug drug_general" data-topicid="9366" href="/z/d/drug information/9366.html" rel="external">alitretinoin</a>. Etretinate is not available in the United States, Europe, and Canada but is still marketed in Japan. Isotretinoin is available in the United States and is an additional option. Alitretinoin (9-cis-retinoic acid), a systemic retinoid approved in Europe and Canada for the treatment of chronic hand eczema, has shown some efficacy in a single patient with diffuse nonepidermolytic PPK (mal de Meleda) [<a href="#rid110">110</a>] and in a few patients with punctate PPK [<a href="#rid111">111,112</a>]. </p><p></p><p class="bulletIndent1">Oral retinoids can be started at a dose of 0.5 mg/kg per day and adjusted up or down, depending on clinical response and tolerability. Treatment should be continued for several months. If improvement is noted, the dose can be tapered to the lowest effective dose. </p><p></p><p class="bulletIndent1">Data from a retrospective study of 30 patients with pachyonychia congenita treated with systemic retinoids indicate that <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a> is more effective than <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> and that low doses (≤25 mg per day) of systemic retinoids are as beneficial as higher doses in thinning plantar calluses and reducing pain [<a href="#rid113">113</a>]. In a few case reports, low-dose acitretin (10 to 25 mg per day) in combination with <a class="drug drug_general" data-topicid="10254" href="/z/d/drug information/10254.html" rel="external">topical salicylic acid</a> and topical corticosteroids was effective in inducing regression of punctate PPK lesions [<a href="#rid107">107,114</a>].</p><p></p><p class="bulletIndent1">Common adverse effects of retinoids include mucocutaneous dryness, cheilitis, hair loss, and elevation of serum triglyceride levels. Oral retinoids are teratogenic. Extreme caution is recommended for use of <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a> in women of childbearing age and girls prior to childbearing age due to concern for teratogenicity and its longer half-life in comparison with <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a>. Pregnancy is contraindicated for <strong>three years</strong> after discontinuing acitretin.</p><p></p><p class="headingAnchor" id="H3035066206"><span class="h2">Surgical treatment</span><span class="headingEndMark"> — </span>Several case reports describe successful treatment of pseudoainhum by specialized hand surgery [<a href="#rid115">115</a>].</p><p class="headingAnchor" id="H3181993894"><span class="h2">Experimental therapies</span><span class="headingEndMark"> — </span>Therapeutic strategies that are being investigated for the treatment of autosomal dominant disorders include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inhibition of cell proliferation signals</strong> – In Olmsted syndrome, aberrant TRPV3 signaling due to <em>TRPV3</em> mutation leads to epidermal growth factor receptor (EGFR) transactivation. Nearly complete remission of severe palmoplantar keratosis was obtained by blocking EGFR transactivation with the EGFR inhibitor <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">erlotinib</a> hydrochloride [<a href="#rid116">116</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Allele-specific RNA interference</strong> – In autosomal dominant PPKs, patients' skin expresses both wild-type and mutated proteins. Gain-of-function of the mutated protein or dominant negative effect to the wild-type protein cause the phenotype. Therefore, specific suppression of the expression of mutated protein is being investigated. Mutated allele-specific RNA interference is one of the candidate methods [<a href="#rid117">117,118</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Readthrough of nonsense mutation</strong> – It is known that <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> induces readthrough of nonsense mutations, and topical use of gentamicin has been tried in PPK Nagashima type, in which the major founder mutation is a nonsense mutation [<a href="#rid119">119</a>].</p><p></p><p class="headingAnchor" id="H2885047329"><span class="h1">GENETIC COUNSELING</span><span class="headingEndMark"> — </span>Referral to a genetic counselor or clinical geneticist should be offered to patients and their families once a hereditary condition has been diagnosed. Genetic counseling provides patients and families with psychosocial support and information regarding the mode of inheritance, risk for the offspring, genetic testing, and availability of prenatal diagnosis. (See  <a class="medical medical_review" href="/z/d/html/103304.html" rel="external">"Genetic counseling: Family history interpretation and risk assessment"</a>.)</p><p class="headingAnchor" id="H1246843668"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/129484.html" rel="external">"Society guideline links: Ichthyosis"</a>.)</p><p class="headingAnchor" id="H942800080"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Hereditary palmoplantar keratodermas (PPKs) are a clinically and genetically heterogeneous group of uncommon disorders characterized by excessive epidermal thickening of the palms and soles. There are multiple classifications of PPK, based on presence of other cutaneous or extracutaneous symptoms, lesion morphology (diffuse, focal, striate, or punctate), or genetic defect  (<a class="graphic graphic_table graphicRef120443 graphicRef120445" href="/z/d/graphic/120443.html" rel="external">table 1A-B</a>). (See <a class="local">'Introduction'</a> above and <a class="local">'Classification'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diffuse PPK includes some of the most common types of PPK. They are characterized by epidermal thickening that involves the entire surface of palms and soles. The hyperkeratosis may show a sharp demarcation at the palmar or plantar border ("nontransgrediens"), such as PPK Vörner type  (<a class="graphic graphic_picture graphicRef120759" href="/z/d/graphic/120759.html" rel="external">picture 1A</a>), or may extend onto the dorsal surfaces of the hands and feet, inner wrists, and the Achilles tendon area ("transgrediens"), such as mal de Meleda  (<a class="graphic graphic_picture graphicRef120762 graphicRef120763" href="/z/d/graphic/120762.html" rel="external">picture 2A-B</a>) and PPK Nagashima type  (<a class="graphic graphic_picture graphicRef120764 graphicRef120765" href="/z/d/graphic/120764.html" rel="external">picture 3A-B</a>). (See <a class="local">'Diffuse palmoplantar keratoderma'</a> above and <a class="local">'Diffuse epidermolytic palmoplantar keratoderma (Vörner type, Unna-Thost type included)'</a> above and <a class="local">'Mal de Meleda'</a> above and <a class="local">'Palmoplantar keratoderma Nagashima type'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Syndromic PPKs encompass a large number of conditions characterized by PPK and involvement of extracutaneous organs. Examples include PPK with deafness, PPK with periodontitis, and PPK associated with cardiomyopathy. (See <a class="local">'Palmoplantar keratodermas with deafness'</a> above and <a class="local">'Palmoplantar keratoderma with periodontitis'</a> above and <a class="local">'Palmoplantar keratoderma associated with cardiomyopathy and woolly hair'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>PPK is a feature of some types of ectodermal dysplasias, such as Clouston syndrome, odonto-onycho-dermal dysplasia, and ectodermal dysplasia/skin fragility syndrome. (See <a class="local">'Palmoplantar keratoderma associated with ectodermal dysplasia'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>PPK is also a feature of several syndromes associated with an increased risk of cutaneous and internal cancers. (See <a class="local">'Palmoplantar keratoderma associated with increased risk of cancer'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The diagnosis of inherited PPK may be challenging due to considerable clinical and genetic heterogeneity of this group of diseases  (<a class="graphic graphic_algorithm graphicRef131627" href="/z/d/graphic/131627.html" rel="external">algorithm 1</a>). It is based on careful physical examination, including the entire skin surface, mucous membranes, nails, and hair, and a detailed personal and family history. Routine histopathology may be helpful in distinguishing epidermolytic from nonepidermolytic PPK. Genetic testing demonstrating a causative mutation in candidate genes is required for a precise diagnosis. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment of hereditary PPK is difficult. Major goals of treatment are softening and flattening the thickened hyperkeratotic skin, improving function and cosmesis, and controlling discomfort and pain. Most patients will benefit from daily to weekly bath soaks followed by gentle mechanical scale removal. Professional foot and hand care may be appropriate for some patients. (See <a class="local">'General measures'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pharmacologic therapy includes topical keratolytics, topical retinoids, and systemic retinoids. However, none of these treatments provide long-term benefit, and recurrence is common after discontinuation (see <a class="local">'Pharmacologic therapies'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Topical keratolytics, such as urea, lactic acid, salicylic acid, or propylene glycol, at various concentrations and in various combinations in cream or ointment formulations can be applied once or twice daily to the affected areas until improvement is noted. Topical keratolytics should be used with caution in children due to the risk of systemic absorption. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Topical retinoids, such as <a class="drug drug_general" data-topicid="9665" href="/z/d/drug information/9665.html" rel="external">tazarotene</a> (0.05% or 0.1% cream) and tretinoin (0.025% to 0.1% cream), are a treatment option for mild PPK. They should be trialed gradually (eg, starting with once or twice weekly application to a small area of the hand or foot) to avoid excessive irritation. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients with disabling PPK, a trial of oral retinoids, including <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a>, <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a>, etretinate, and <a class="drug drug_general" data-topicid="9366" href="/z/d/drug information/9366.html" rel="external">alitretinoin</a>, may be attempted. Oral retinoids can be started at a dose of 0.5 mg/kg per day and adjusted up or down, depending on response and tolerability. If improvement is noted, the dose can be tapered to the lowest effective dose.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with syndromic PPK require an individualized, multidisciplinary approach, in addition to dermatologic care, based on the type and severity of associated clinical signs and symptoms. (See <a class="local">'Syndromic palmoplantar keratoderma'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Has C, Technau-Hafsi K. Palmoplantar keratodermas: clinical and genetic aspects. J Dtsch Dermatol Ges 2016; 14:123.</a></li><li><a class="nounderline abstract_t">Schiller S, Seebode C, Hennies HC, et al. Palmoplantar keratoderma (PPK): acquired and genetic causes of a not so rare disease. J Dtsch Dermatol Ges 2014; 12:781.</a></li><li><a class="nounderline abstract_t">Guerra L, Castori M, Didona B, et al. Hereditary palmoplantar keratodermas. Part I. Non-syndromic palmoplantar keratodermas: classification, clinical and genetic features. J Eur Acad Dermatol Venereol 2018; 32:704.</a></li><li><a class="nounderline abstract_t">Guerra L, Castori M, Didona B, et al. Hereditary palmoplantar keratodermas. Part II: syndromic palmoplantar keratodermas - Diagnostic algorithm and principles of therapy. J Eur Acad Dermatol Venereol 2018; 32:899.</a></li><li><a class="nounderline abstract_t">Sakiyama T, Kubo A. Hereditary palmoplantar keratoderma "clinical and genetic differential diagnosis". J Dermatol 2016; 43:264.</a></li><li><a class="nounderline abstract_t">Covello SP, Irvine AD, McKenna KE, et al. Mutations in keratin K9 in kindreds with epidermolytic palmoplantar keratoderma and epidemiology in Northern Ireland. J Invest Dermatol 1998; 111:1207.</a></li><li><a class="nounderline abstract_t">Kubo A, Shiohama A, Sasaki T, et al. Mutations in SERPINB7, encoding a member of the serine protease inhibitor superfamily, cause Nagashima-type palmoplantar keratosis. Am J Hum Genet 2013; 93:945.</a></li><li><a class="nounderline abstract_t">Kim WB, Shelley AJ, Novice K, et al. Drug-induced phototoxicity: A systematic review. J Am Acad Dermatol 2018; 79:1069.</a></li><li><a class="nounderline abstract_t">Hovorka O, Ehlers E. Mal de Meleda. Arch Dermatol Res 1897; 40:251.</a></li><li><a class="nounderline abstract_t">Nesbitt LT Jr, Rothschild H, Ichinose H, et al. Acral keratoderma. Arch Dermatol 1975; 111:763.</a></li><li><a class="nounderline abstract_t">Mitsuhashi Y, Hashimato I. Keratosis palmoplantaris Nagashima. Dermatologica 1989; 179:231.</a></li><li><a class="nounderline abstract_t">Kabashima K, Sakabe J, Yamada Y, Tokura Y. "Nagashima-type" keratosis as a novel entity in the palmoplantar keratoderma category. Arch Dermatol 2008; 144:375.</a></li><li><a class="nounderline abstract_t">Lind L, Lundström A, Hofer PA, Holmgren G. The gene for diffuse palmoplantar keratoderma of the type found in northern Sweden is localized to chromosome 12q11-q13. Hum Mol Genet 1994; 3:1789.</a></li><li><a class="nounderline abstract_t">Gamborg Nielsen P. Two different clinical and genetic forms of hereditary palmoplantar keratoderma in the northernmost county of Sweden. Clin Genet 1985; 28:361.</a></li><li><a class="nounderline abstract_t">Kastl I, Anton-Lamprecht I, Gamborg Nielsen P. Hereditary palmoplantar keratosis of the Gamborg Nielsen type. Clinical and ultrastructural characteristics of a new type of autosomal recessive palmoplantar keratosis. Arch Dermatol Res 1990; 282:363.</a></li><li><a class="nounderline abstract_t">GREITHER A. [Keratosis extremitatum hereditaria progrediens with genetic dominant]. Hautarzt 1952; 3:198.</a></li><li><a class="nounderline abstract_t">Sybert VP, Dale BA, Holbrook KA. Palmar-plantar keratoderma. A clinical, ultrastructural, and biochemical study. J Am Acad Dermatol 1988; 18:75.</a></li><li><a class="nounderline abstract_t">Reis A, Hennies HC, Langbein L, et al. Keratin 9 gene mutations in epidermolytic palmoplantar keratoderma (EPPK). Nat Genet 1994; 6:174.</a></li><li><a class="nounderline abstract_t">Wennerstrand LM, Klingberg MH, Hofer PA, et al. A de novo mutation in the keratin 9 gene in a family with epidermolytic palmoplantar keratoderma from northern Sweden. Acta Derm Venereol 2003; 83:135.</a></li><li><a class="nounderline abstract_t">Küster W, Becker A. Indication for the identity of palmoplantar keratoderma type Unna-Thost with type Vörner. Thost's family revisited 110 years later. Acta Derm Venereol 1992; 72:120.</a></li><li><a class="nounderline abstract_t">Küster W, Reis A, Hennies HC. Epidermolytic palmoplantar keratoderma of Vörner: re-evaluation of Vörner's original family and identification of a novel keratin 9 mutation. Arch Dermatol Res 2002; 294:268.</a></li><li><a class="nounderline abstract_t">Keren H, Bergman R, Mizrachi M, et al. Diffuse nonepidermolytic palmoplantar keratoderma caused by a recurrent nonsense mutation in DSG1. Arch Dermatol 2005; 141:625.</a></li><li><a class="nounderline abstract_t">Samuelov L, Sarig O, Harmon RM, et al. Desmoglein 1 deficiency results in severe dermatitis, multiple allergies and metabolic wasting. Nat Genet 2013; 45:1244.</a></li><li><a class="nounderline abstract_t">Fischer J, Bouadjar B, Heilig R, et al. Mutations in the gene encoding SLURP-1 in Mal de Meleda. Hum Mol Genet 2001; 10:875.</a></li><li><a class="nounderline abstract_t">Nellen RG, Steijlen PM, Hennies HC, et al. Haplotype analysis in western European patients with mal de Meleda: founder effect for the W15R mutation in the SLURP1 gene. Br J Dermatol 2013; 168:1372.</a></li><li><a class="nounderline abstract_t">Nielsen PG. Hereditary palmoplantar keratoderma and dermatophytosis in the northernmost county of Sweden (Norrbotten). Acta Derm Venereol Suppl (Stockh) 1994; 188:1.</a></li><li><a class="nounderline abstract_t">Zhao L, Vahlquist A, Virtanen M, et al. Palmoplantar keratoderma of the Gamborg-Nielsen type is caused by mutations in the SLURP1 gene and represents a variant of Mal de Meleda. Acta Derm Venereol 2014; 94:707.</a></li><li><a class="nounderline abstract_t">Kubo A. Nagashima-type palmoplantar keratosis: a common Asian type caused by SERPINB7 protease inhibitor deficiency. J Invest Dermatol 2014; 134:2076.</a></li><li><a class="nounderline abstract_t">Mohamad J, Sarig O, Malki L, et al. Loss-of-Function Variants in SERPINA12 Underlie Autosomal Recessive Palmoplantar Keratoderma. J Invest Dermatol 2020; 140:2178.</a></li><li><a class="nounderline abstract_t">Liu Y, Tan Y, Liu J, et al. Novel and founder variants of SERPINA12 in Chinese patients with autosomal recessive palmoplantar keratoderma. Br J Dermatol 2022; 187:267.</a></li><li><a class="nounderline abstract_t">Cao X, Yin J, Wang H, et al. Mutation in AQP5, encoding aquaporin 5, causes palmoplantar keratoderma Bothnia type. J Invest Dermatol 2014; 134:284.</a></li><li><a class="nounderline abstract_t">Blaydon DC, Lind LK, Plagnol V, et al. Mutations in AQP5, encoding a water-channel protein, cause autosomal-dominant diffuse nonepidermolytic palmoplantar keratoderma. Am J Hum Genet 2013; 93:330.</a></li><li><a class="nounderline abstract_t">Flückiger R, Itin PH. Keratosis extremitatum (Greither's disease): clinical features, histology, ultrastructure. Dermatology 1993; 187:309.</a></li><li><a class="nounderline abstract_t">Gach JE, Munro CS, Lane EB, et al. Two families with Greither's syndrome caused by a keratin 1 mutation. J Am Acad Dermatol 2005; 53:S225.</a></li><li><a class="nounderline abstract_t">Eliason MJ, Leachman SA, Feng BJ, et al. A review of the clinical phenotype of 254 patients with genetically confirmed pachyonychia congenita. J Am Acad Dermatol 2012; 67:680.</a></li><li><a class="nounderline abstract_t">Shamsher MK, Navsaria HA, Stevens HP, et al. Novel mutations in keratin 16 gene underly focal non-epidermolytic palmoplantar keratoderma (NEPPK) in two families. Hum Mol Genet 1995; 4:1875.</a></li><li><a class="nounderline abstract_t">Smith FJ, Fisher MP, Healy E, et al. Novel keratin 16 mutations and protein expression studies in pachyonychia congenita type 1 and focal palmoplantar keratoderma. Exp Dermatol 2000; 9:170.</a></li><li><a class="nounderline abstract_t">Wilson NJ, Messenger AG, Leachman SA, et al. Keratin K6c mutations cause focal palmoplantar keratoderma. J Invest Dermatol 2010; 130:425.</a></li><li><a class="nounderline abstract_t">Akasaka E, Nakano H, Nakano A, et al. Diffuse and focal palmoplantar keratoderma can be caused by a keratin 6c mutation. Br J Dermatol 2011; 165:1290.</a></li><li><a class="nounderline abstract_t">Kubo A, Oura Y, Hirano T, et al. Collapse of the keratin filament network through the expression of mutant keratin 6c observed in a case of focal plantar keratoderma. J Dermatol 2013; 40:553.</a></li><li><a class="nounderline abstract_t">Milingou M, Wood P, Masouyé I, et al. Focal palmoplantar keratoderma caused by an autosomal dominant inherited mutation in the desmoglein 1 gene. Dermatology 2006; 212:117.</a></li><li><a class="nounderline abstract_t">Rickman L, Simrak D, Stevens HP, et al. N-terminal deletion in a desmosomal cadherin causes the autosomal dominant skin disease striate palmoplantar keratoderma. Hum Mol Genet 1999; 8:971.</a></li><li><a class="nounderline abstract_t">Bergman R, Hershkovitz D, Fuchs D, et al. Disadhesion of epidermal keratinocytes: a histologic clue to palmoplantar keratodermas caused by DSG1 mutations. J Am Acad Dermatol 2010; 62:107.</a></li><li><a class="nounderline abstract_t">Barber AG, Wajid M, Columbo M, et al. Striate palmoplantar keratoderma resulting from a frameshift mutation in the desmoglein 1 gene. J Dermatol Sci 2007; 45:161.</a></li><li><a class="nounderline abstract_t">Lovgren ML, McAleer MA, Irvine AD, et al. Mutations in desmoglein 1 cause diverse inherited palmoplantar keratoderma phenotypes: implications for genetic screening. Br J Dermatol 2017; 176:1345.</a></li><li><a class="nounderline abstract_t">He Y, Zeng K, Zhang X, et al. A gain-of-function mutation in TRPV3 causes focal palmoplantar keratoderma in a Chinese family. J Invest Dermatol 2015; 135:907.</a></li><li><a class="nounderline abstract_t">Lin Z, Chen Q, Lee M, et al. Exome sequencing reveals mutations in TRPV3 as a cause of Olmsted syndrome. Am J Hum Genet 2012; 90:558.</a></li><li><a class="nounderline abstract_t">Armstrong DK, McKenna KE, Purkis PE, et al. Haploinsufficiency of desmoplakin causes a striate subtype of palmoplantar keratoderma. Hum Mol Genet 1999; 8:143.</a></li><li><a class="nounderline abstract_t">Whittock NV, Smith FJ, Wan H, et al. Frameshift mutation in the V2 domain of human keratin 1 results in striate palmoplantar keratoderma. J Invest Dermatol 2002; 118:838.</a></li><li><a class="nounderline abstract_t">Ramot Y, Molho-Pessach V, Meir T, et al. Mutation in KANK2, encoding a sequestering protein for steroid receptor coactivators, causes keratoderma and woolly hair. J Med Genet 2014; 51:388.</a></li><li><a class="nounderline abstract_t">Giehl KA, Eckstein GN, Pasternack SM, et al. Nonsense mutations in AAGAB cause punctate palmoplantar keratoderma type Buschke-Fischer-Brauer. Am J Hum Genet 2012; 91:754.</a></li><li><a class="nounderline abstract_t">Pohler E, Mamai O, Hirst J, et al. Haploinsufficiency for AAGAB causes clinically heterogeneous forms of punctate palmoplantar keratoderma. Nat Genet 2012; 44:1272.</a></li><li><a class="nounderline abstract_t">Zamiri M, Wilson NJ, Mackenzie A, et al. Painful punctate palmoplantar keratoderma due to heterozygous mutations in AAGAB. Br J Dermatol 2019; 180:1250.</a></li><li><a class="nounderline abstract_t">Guo BR, Zhang X, Chen G, et al. Exome sequencing identifies a COL14A1 mutation in a large Chinese pedigree with punctate palmoplantar keratoderma. J Med Genet 2012; 49:563.</a></li><li><a class="nounderline abstract_t">Sakas EL, Gentry RH. Porokeratosis punctata palmaris et plantaris (punctate porokeratosis). Case report and literature review. J Am Acad Dermatol 1985; 13:908.</a></li><li><a class="nounderline abstract_t">Lestringant GG, Berge T. Porokeratosis punctata palmaris et plantaris. A new entity? Arch Dermatol 1989; 125:816.</a></li><li><a class="nounderline abstract_t">Lopes JF, de Almeida HL Jr, da Cunha Filho RR, et al. Ultrastructure of acrokeratoelastoidosis. J Eur Acad Dermatol Venereol 2018; 32:e165.</a></li><li><a class="nounderline abstract_t">van Geel M, van Steensel MA, Küster W, et al. HID and KID syndromes are associated with the same connexin 26 mutation. Br J Dermatol 2002; 146:938.</a></li><li><a class="nounderline abstract_t">Heathcote K, Syrris P, Carter ND, Patton MA. A connexin 26 mutation causes a syndrome of sensorineural hearing loss and palmoplantar hyperkeratosis (MIM 148350). J Med Genet 2000; 37:50.</a></li><li class="breakAll">Saleh D, Tanner LS. Vohwinkel syndrome. In: StatPearls, StatPearls Publishing, Treasure Island (FL) 2019.</li><li><a class="nounderline abstract_t">Birkenhäger R, Lüblinghoff N, Prera E, et al. Autosomal dominant prelingual hearing loss with palmoplantar keratoderma syndrome: Variability in clinical expression from mutations of R75W and R75Q in the GJB2 gene. Am J Med Genet A 2010; 152A:1798.</a></li><li><a class="nounderline abstract_t">de Zwart-Storm EA, van Geel M, van Neer PA, et al. A novel missense mutation in the second extracellular domain of GJB2, p.Ser183Phe, causes a syndrome of focal palmoplantar keratoderma with deafness. Am J Pathol 2008; 173:1113.</a></li><li><a class="nounderline abstract_t">Bart RS, Pumphrey RE. Knuckle pads, leukonychia and deafness. A dominantly inherited syndrome. N Engl J Med 1967; 276:202.</a></li><li><a class="nounderline abstract_t">Hyman CH, Cohen PR. Report of a family with idiopathic knuckle pads and review of idiopathic and disease-associated knuckle pads. Dermatol Online J 2013; 19:18177.</a></li><li><a class="nounderline abstract_t">Caria H, Matos T, Oliveira-Soares R, et al. A7445G mtDNA mutation present in a Portuguese family exhibiting hereditary deafness and palmoplantar keratoderma. J Eur Acad Dermatol Venereol 2005; 19:455.</a></li><li><a class="nounderline abstract_t">Sevior KB, Hatamochi A, Stewart IA, et al. Mitochondrial A7445G mutation in two pedigrees with palmoplantar keratoderma and deafness. Am J Med Genet 1998; 75:179.</a></li><li><a class="nounderline abstract_t">Pohler E, Cunningham F, Sandilands A, et al. Novel autosomal dominant mutation in loricrin presenting as prominent ichthyosis. Br J Dermatol 2015; 173:1291.</a></li><li><a class="nounderline abstract_t">Morice-Picard F, Jonca N, Pichery M, et al. KLICK syndrome: recognizable phenotype and hot-spot POMP mutation. J Eur Acad Dermatol Venereol 2017; 31:e154.</a></li><li><a class="nounderline abstract_t">Onnis G, Bourrat E, Jonca N, et al. KLICK syndrome: an unusual phenotype. Br J Dermatol 2018; 178:1445.</a></li><li><a class="nounderline abstract_t">Ketterer S, Gomez-Auli A, Hillebrand LE, et al. Inherited diseases caused by mutations in cathepsin protease genes. FEBS J 2017; 284:1437.</a></li><li><a class="nounderline abstract_t">Sreeramulu B, Shyam ND, Ajay P, Suman P. Papillon-Lefèvre syndrome: clinical presentation and management options. Clin Cosmet Investig Dent 2015; 7:75.</a></li><li><a class="nounderline abstract_t">Jose J, Bartlett K, Salgado C, Gutierrez NM. Papillon-Lefèvre syndrome: review of imaging findings and current literature. Foot Ankle Spec 2015; 8:139.</a></li><li><a class="nounderline abstract_t">Ullbro C, Crossner CG, Nederfors T, et al. Dermatologic and oral findings in a cohort of 47 patients with Papillon-Lefèvre syndrome. J Am Acad Dermatol 2003; 48:345.</a></li><li><a class="nounderline abstract_t">Hart TC, Hart PS, Michalec MD, et al. Haim-Munk syndrome and Papillon-Lefèvre syndrome are allelic mutations in cathepsin C. J Med Genet 2000; 37:88.</a></li><li><a class="nounderline abstract_t">Norgett EE, Hatsell SJ, Carvajal-Huerta L, et al. Recessive mutation in desmoplakin disrupts desmoplakin-intermediate filament interactions and causes dilated cardiomyopathy, woolly hair and keratoderma. Hum Mol Genet 2000; 9:2761.</a></li><li><a class="nounderline abstract_t">Pigors M, Schwieger-Briel A, Cosgarea R, et al. Desmoplakin mutations with palmoplantar keratoderma, woolly hair and cardiomyopathy. Acta Derm Venereol 2015; 95:337.</a></li><li><a class="nounderline abstract_t">Carvajal-Huerta L. Epidermolytic palmoplantar keratoderma with woolly hair and dilated cardiomyopathy. J Am Acad Dermatol 1998; 39:418.</a></li><li><a class="nounderline abstract_t">Norgett EE, Lucke TW, Bowers B, et al. Early death from cardiomyopathy in a family with autosomal dominant striate palmoplantar keratoderma and woolly hair associated with a novel insertion mutation in desmoplakin. J Invest Dermatol 2006; 126:1651.</a></li><li><a class="nounderline abstract_t">Boulé S, Fressart V, Laux D, et al. Expanding the phenotype associated with a desmoplakin dominant mutation: Carvajal/Naxos syndrome associated with leukonychia and oligodontia. Int J Cardiol 2012; 161:50.</a></li><li><a class="nounderline abstract_t">Li GL, Saguner AM, Fontaine GH. Naxos disease: from the origin to today. Orphanet J Rare Dis 2018; 13:74.</a></li><li><a class="nounderline abstract_t">Simpson MA, Mansour S, Ahnood D, et al. Homozygous mutation of desmocollin-2 in arrhythmogenic right ventricular cardiomyopathy with mild palmoplantar keratoderma and woolly hair. Cardiology 2009; 113:28.</a></li><li><a class="nounderline abstract_t">Lamartine J, Munhoz Essenfelder G, Kibar Z, et al. Mutations in GJB6 cause hidrotic ectodermal dysplasia. Nat Genet 2000; 26:142.</a></li><li><a class="nounderline abstract_t">Lugassy J, McGrath JA, Itin P, et al. KRT14 haploinsufficiency results in increased susceptibility of keratinocytes to TNF-alpha-induced apoptosis and causes Naegeli-Franceschetti-Jadassohn syndrome. J Invest Dermatol 2008; 128:1517.</a></li><li><a class="nounderline abstract_t">Adaimy L, Chouery E, Megarbane H, et al. Mutation in WNT10A is associated with an autosomal recessive ectodermal dysplasia: the odonto-onycho-dermal dysplasia. Am J Hum Genet 2007; 81:821.</a></li><li><a class="nounderline abstract_t">Kantaputra P, Kaewgahya M, Jotikasthira D, Kantaputra W. Tricho-odonto-onycho-dermal dysplasia and WNT10A mutations. Am J Med Genet A 2014; 164A:1041.</a></li><li><a class="nounderline abstract_t">Tziotzios C, Petrof G, Liu L, et al. Clinical features and WNT10A mutations in seven unrelated cases of Schöpf-Schulz-Passarge syndrome. Br J Dermatol 2014; 171:1211.</a></li><li><a class="nounderline abstract_t">McGrath JA, McMillan JR, Shemanko CS, et al. Mutations in the plakophilin 1 gene result in ectodermal dysplasia/skin fragility syndrome. Nat Genet 1997; 17:240.</a></li><li><a class="nounderline abstract_t">Whittock NV, Wan H, Morley SM, et al. Compound heterozygosity for non-sense and mis-sense mutations in desmoplakin underlies skin fragility/woolly hair syndrome. J Invest Dermatol 2002; 118:232.</a></li><li><a class="nounderline abstract_t">McGrath JA, Mellerio JE. Ectodermal dysplasia-skin fragility syndrome. Dermatol Clin 2010; 28:125.</a></li><li><a class="nounderline abstract_t">Lin Z, Zhao J, Nitoiu D, et al. Loss-of-function mutations in CAST cause peeling skin, leukonychia, acral punctate keratoses, cheilitis, and knuckle pads. Am J Hum Genet 2015; 96:440.</a></li><li><a class="nounderline abstract_t">Cole LA. Hypopigmentation with punctate keratosis of the palms and soles. Arch Dermatol 1976; 112:998.</a></li><li><a class="nounderline abstract_t">Eytan O, Morice-Picard F, Sarig O, et al. Cole Disease Results from Mutations in ENPP1. Am J Hum Genet 2013; 93:752.</a></li><li><a class="nounderline abstract_t">Blaydon DC, Etheridge SL, Risk JM, et al. RHBDF2 mutations are associated with tylosis, a familial esophageal cancer syndrome. Am J Hum Genet 2012; 90:340.</a></li><li><a class="nounderline abstract_t">Ellis A, Risk JM, Maruthappu T, Kelsell DP. Tylosis with oesophageal cancer: Diagnosis, management and molecular mechanisms. Orphanet J Rare Dis 2015; 10:126.</a></li><li><a class="nounderline abstract_t">Çelik NS, Yaşar Ş, Aytekin S, Güneş P. A Rare Syndrome Resembling Scleroderma: Huriez Syndrome. Skin Appendage Disord 2018; 4:82.</a></li><li><a class="nounderline abstract_t">Günther C, Lee-Kirsch MA, Eckhard J, et al. SMARCAD1 Haploinsufficiency Underlies Huriez Syndrome and Associated Skin Cancer Susceptibility. J Invest Dermatol 2018; 138:1428.</a></li><li class="breakAll">Garofola C, Gross GP. Cowden disease (multiple hamartoma syndrome). In: StatPearls, StatPearls Publishing, Treasure Island (FL) 2018.</li><li><a class="nounderline abstract_t">Pilarski R, Burt R, Kohlman W, et al. Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria. J Natl Cancer Inst 2013; 105:1607.</a></li><li><a class="nounderline abstract_t">Duchatelet S, Hovnanian A. Olmsted syndrome: clinical, molecular and therapeutic aspects. Orphanet J Rare Dis 2015; 10:33.</a></li><li><a class="nounderline abstract_t">Yoneda K, Kubo A, Nomura T, et al. Japanese guidelines for the management of palmoplantar keratoderma. J Dermatol 2021; 48:e353.</a></li><li><a class="nounderline abstract_t">Patel S, Zirwas M, English JC 3rd. Acquired palmoplantar keratoderma. Am J Clin Dermatol 2007; 8:1.</a></li><li><a class="nounderline abstract_t">Mendes-Bastos P. Plantar keratoderma climatericum: Successful improvement with a topical estriol cream. J Cosmet Dermatol 2018; 17:811.</a></li><li><a class="nounderline abstract_t">Deschamps P, Leroy D, Pedailles S, Mandard JC. Keratoderma climactericum (Haxthausen's disease): clinical signs, laboratory findings and etretinate treatment in 10 patients. Dermatologica 1986; 172:258.</a></li><li><a class="nounderline abstract_t">Duretz C, Antonicelli F, Muller C, et al. Association of Transient Palmoplantar Keratoderma With Clinical and Immunologic Characteristics of Bullous Pemphigoid. JAMA Dermatol 2019; 155:216.</a></li><li><a class="nounderline abstract_t">Fania L, Didona D, Pacifico V, et al. Bullous pemphigoid with hyperkeratosis and palmoplantar keratoderma: Three cases. J Dermatol 2018; 45:1135.</a></li><li><a class="nounderline abstract_t">Mazereeuw-Hautier J, Vahlquist A, Traupe H, et al. Management of congenital ichthyoses: European guidelines of care, part one. Br J Dermatol 2019; 180:272.</a></li><li><a class="nounderline abstract_t">Jo JW, Jeong DS, Kim CY. Case of punctate palmoplantar keratoderma type I treated with combination of low-dose oral acitretin and topical salicylic acid and steroid. J Dermatol 2018; 45:609.</a></li><li><a class="nounderline abstract_t">Marukian NV, Levinsohn JL, Craiglow BG, et al. Palmoplantar Keratoderma in Costello Syndrome Responsive to Acitretin. Pediatr Dermatol 2017; 34:160.</a></li><li><a class="nounderline abstract_t">Sarma N, Ghosh C, Kar S, Bazmi BA. Low-dose acitretin in Papillon-Lefèvre syndrome: treatment and 1-year follow-up. Dermatol Ther 2015; 28:28.</a></li><li><a class="nounderline abstract_t">Park HK, Kim EJ, Ko JY. Alitretinoin: treatment for refractory palmoplantar keratoderma. Br J Dermatol 2016; 174:1143.</a></li><li><a class="nounderline abstract_t">Yilmaz P, Medvecz M, Kohlhase J, et al. Alitretinoin in punctate palmoplantar keratoderma. Br J Dermatol 2019; 180:931.</a></li><li><a class="nounderline abstract_t">Raone B, Raboni R, Patrizi A. Alitretinoin: a new treatment option for hereditary punctate palmoplantar keratoderma (Brauer-Buschke-Fischer syndrome). J Am Acad Dermatol 2014; 71:e48.</a></li><li><a class="nounderline abstract_t">Gruber R, Edlinger M, Kaspar RL, et al. An appraisal of oral retinoids in the treatment of pachyonychia congenita. J Am Acad Dermatol 2012; 66:e193.</a></li><li><a class="nounderline abstract_t">Erkek E, Erdogan S, Tuncez F, et al. Type I hereditary punctate keratoderma associated with widespread lentigo simplex and successfully treated with low-dose oral acitretin. Arch Dermatol 2006; 142:1076.</a></li><li><a class="nounderline abstract_t">Simkin D, Ho JD, Simkin DJ, Tomany K. A novel association of pseudoainhum and epidermolytic ichthyosis, successfully treated with full thickness skin graft after failed z-plasty repair. Dermatol Online J 2018; 24.</a></li><li><a class="nounderline abstract_t">Greco C, Leclerc-Mercier S, Chaumon S, et al. Use of Epidermal Growth Factor Receptor Inhibitor Erlotinib to Treat Palmoplantar Keratoderma in Patients With Olmsted Syndrome Caused by TRPV3 Mutations. JAMA Dermatol 2020; 156:191.</a></li><li><a class="nounderline abstract_t">Hickerson RP, Smith FJ, McLean WH, et al. SiRNA-mediated selective inhibition of mutant keratin mRNAs responsible for the skin disorder pachyonychia congenita. Ann N Y Acad Sci 2006; 1082:56.</a></li><li><a class="nounderline abstract_t">Smith FJ, Hickerson RP, Sayers JM, et al. Development of therapeutic siRNAs for pachyonychia congenita. J Invest Dermatol 2008; 128:50.</a></li><li><a class="nounderline abstract_t">Ohguchi Y, Nomura T, Suzuki S, et al. Gentamicin-Induced Readthrough and Nonsense-Mediated mRNA Decay of SERPINB7 Nonsense Mutant Transcripts. J Invest Dermatol 2018; 138:836.</a></li></ol></div><div id="topicVersionRevision">Topic 110147 Version 8.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26819106" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Palmoplantar keratodermas: clinical and genetic aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25176457" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Palmoplantar keratoderma (PPK): acquired and genetic causes of a not so rare disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29489036" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Hereditary palmoplantar keratodermas. Part I. Non-syndromic palmoplantar keratodermas: classification, clinical and genetic features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29397027" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Hereditary palmoplantar keratodermas. Part II: syndromic palmoplantar keratodermas - Diagnostic algorithm and principles of therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26945534" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Hereditary palmoplantar keratoderma "clinical and genetic differential diagnosis".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9856842" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Mutations in keratin K9 in kindreds with epidermolytic palmoplantar keratoderma and epidemiology in Northern Ireland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24207119" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Mutations in SERPINB7, encoding a member of the serine protease inhibitor superfamily, cause Nagashima-type palmoplantar keratosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30003982" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Drug-induced phototoxicity: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Mal de Meleda</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1137423" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Acral keratoderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Keratosis palmoplantaris Nagashima</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18347294" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : "Nagashima-type" keratosis as a novel entity in the palmoplantar keratoderma category.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7531539" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The gene for diffuse palmoplantar keratoderma of the type found in northern Sweden is localized to chromosome 12q11-q13.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2935332" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Two different clinical and genetic forms of hereditary palmoplantar keratoderma in the northernmost county of Sweden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2260881" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Hereditary palmoplantar keratosis of the Gamborg Nielsen type. Clinical and ultrastructural characteristics of a new type of autosomal recessive palmoplantar keratosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14945735" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : [Keratosis extremitatum hereditaria progrediens with genetic dominant].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2450111" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Palmar-plantar keratoderma. A clinical, ultrastructural, and biochemical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7512862" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Keratin 9 gene mutations in epidermolytic palmoplantar keratoderma (EPPK).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12735645" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A de novo mutation in the keratin 9 gene in a family with epidermolytic palmoplantar keratoderma from northern Sweden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1350396" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Indication for the identity of palmoplantar keratoderma type Unna-Thost with type Vörner. Thost's family revisited 110 years later.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12192490" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Epidermolytic palmoplantar keratoderma of Vörner: re-evaluation of Vörner's original family and identification of a novel keratin 9 mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15897387" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Diffuse nonepidermolytic palmoplantar keratoderma caused by a recurrent nonsense mutation in DSG1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23974871" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Desmoglein 1 deficiency results in severe dermatitis, multiple allergies and metabolic wasting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11285253" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Mutations in the gene encoding SLURP-1 in Mal de Meleda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23290002" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Haplotype analysis in western European patients with mal de Meleda: founder effect for the W15R mutation in the SLURP1 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9868488" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Hereditary palmoplantar keratoderma and dermatophytosis in the northernmost county of Sweden (Norrbotten).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24604124" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Palmoplantar keratoderma of the Gamborg-Nielsen type is caused by mutations in the SLURP1 gene and represents a variant of Mal de Meleda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25029323" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Nagashima-type palmoplantar keratosis: a common Asian type caused by SERPINB7 protease inhibitor deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32247861" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Loss-of-Function Variants in SERPINA12 Underlie Autosomal Recessive Palmoplantar Keratoderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35199331" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Novel and founder variants of SERPINA12 in Chinese patients with autosomal recessive palmoplantar keratoderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23867895" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Mutation in AQP5, encoding aquaporin 5, causes palmoplantar keratoderma Bothnia type.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23830519" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Mutations in AQP5, encoding a water-channel protein, cause autosomal-dominant diffuse nonepidermolytic palmoplantar keratoderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8274799" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Keratosis extremitatum (Greither's disease): clinical features, histology, ultrastructure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16227096" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Two families with Greither's syndrome caused by a keratin 1 mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22264670" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : A review of the clinical phenotype of 254 patients with genetically confirmed pachyonychia congenita.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8595410" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Novel mutations in keratin 16 gene underly focal non-epidermolytic palmoplantar keratoderma (NEPPK) in two families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10839714" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Novel keratin 16 mutations and protein expression studies in pachyonychia congenita type 1 and focal palmoplantar keratoderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19609311" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Keratin K6c mutations cause focal palmoplantar keratoderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21801157" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Diffuse and focal palmoplantar keratoderma can be caused by a keratin 6c mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23662636" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Collapse of the keratin filament network through the expression of mutant keratin 6c observed in a case of focal plantar keratoderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16484817" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Focal palmoplantar keratoderma caused by an autosomal dominant inherited mutation in the desmoglein 1 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10332028" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : N-terminal deletion in a desmosomal cadherin causes the autosomal dominant skin disease striate palmoplantar keratoderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20082890" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Disadhesion of epidermal keratinocytes: a histologic clue to palmoplantar keratodermas caused by DSG1 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17194569" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Striate palmoplantar keratoderma resulting from a frameshift mutation in the desmoglein 1 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27534273" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Mutations in desmoglein 1 cause diverse inherited palmoplantar keratoderma phenotypes: implications for genetic screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25285920" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : A gain-of-function mutation in TRPV3 causes focal palmoplantar keratoderma in a Chinese family.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22405088" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Exome sequencing reveals mutations in TRPV3 as a cause of Olmsted syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9887343" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Haploinsufficiency of desmoplakin causes a striate subtype of palmoplantar keratoderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11982762" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Frameshift mutation in the V2 domain of human keratin 1 results in striate palmoplantar keratoderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24671081" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Mutation in KANK2, encoding a sequestering protein for steroid receptor coactivators, causes keratoderma and woolly hair.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23000146" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Nonsense mutations in AAGAB cause punctate palmoplantar keratoderma type Buschke-Fischer-Brauer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23064416" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Haploinsufficiency for AAGAB causes clinically heterogeneous forms of punctate palmoplantar keratoderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30451279" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Painful punctate palmoplantar keratoderma due to heterozygous mutations in AAGAB.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22972947" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Exome sequencing identifies a COL14A1 mutation in a large Chinese pedigree with punctate palmoplantar keratoderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2933431" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Porokeratosis punctata palmaris et plantaris (punctate porokeratosis). Case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2525006" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Porokeratosis punctata palmaris et plantaris. A new entity?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29080320" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Ultrastructure of acrokeratoelastoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12072059" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : HID and KID syndromes are associated with the same connexin 26 mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10633135" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : A connexin 26 mutation causes a syndrome of sensorineural hearing loss and palmoplantar hyperkeratosis (MIM 148350).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10633135" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : A connexin 26 mutation causes a syndrome of sensorineural hearing loss and palmoplantar hyperkeratosis (MIM 148350).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20583176" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Autosomal dominant prelingual hearing loss with palmoplantar keratoderma syndrome: Variability in clinical expression from mutations of R75W and R75Q in the GJB2 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18787097" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : A novel missense mutation in the second extracellular domain of GJB2, p.Ser183Phe, causes a syndrome of focal palmoplantar keratoderma with deafness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6015974" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Knuckle pads, leukonychia and deafness. A dominantly inherited syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24011277" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Report of a family with idiopathic knuckle pads and review of idiopathic and disease-associated knuckle pads.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15987292" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : A7445G mtDNA mutation present in a Portuguese family exhibiting hereditary deafness and palmoplantar keratoderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9450881" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Mitochondrial A7445G mutation in two pedigrees with palmoplantar keratoderma and deafness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25965869" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Novel autosomal dominant mutation in loricrin presenting as prominent ichthyosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27503413" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : KLICK syndrome: recognizable phenotype and hot-spot POMP mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29315485" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : KLICK syndrome: an unusual phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27926992" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Inherited diseases caused by mutations in cathepsin protease genes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26203280" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Papillon-Lefèvre syndrome: clinical presentation and management options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25421448" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Papillon-Lefèvre syndrome: review of imaging findings and current literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12637913" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Dermatologic and oral findings in a cohort of 47 patients with Papillon-Lefèvre syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10662807" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Haim-Munk syndrome and Papillon-Lefèvre syndrome are allelic mutations in cathepsin C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11063735" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Recessive mutation in desmoplakin disrupts desmoplakin-intermediate filament interactions and causes dilated cardiomyopathy, woolly hair and keratoderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25227139" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Desmoplakin mutations with palmoplantar keratoderma, woolly hair and cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9738775" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Epidermolytic palmoplantar keratoderma with woolly hair and dilated cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16628197" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Early death from cardiomyopathy in a family with autosomal dominant striate palmoplantar keratoderma and woolly hair associated with a novel insertion mutation in desmoplakin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22795705" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Expanding the phenotype associated with a desmoplakin dominant mutation: Carvajal/Naxos syndrome associated with leukonychia and oligodontia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29747658" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Naxos disease: from the origin to today.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18957847" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Homozygous mutation of desmocollin-2 in arrhythmogenic right ventricular cardiomyopathy with mild palmoplantar keratoderma and woolly hair.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11017065" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Mutations in GJB6 cause hidrotic ectodermal dysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18049449" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : KRT14 haploinsufficiency results in increased susceptibility of keratinocytes to TNF-alpha-induced apoptosis and causes Naegeli-Franceschetti-Jadassohn syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17847007" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Mutation in WNT10A is associated with an autosomal recessive ectodermal dysplasia: the odonto-onycho-dermal dysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24458874" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Tricho-odonto-onycho-dermal dysplasia and WNT10A mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24902757" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Clinical features and WNT10A mutations in seven unrelated cases of Schöpf-Schulz-Passarge syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9326952" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Mutations in the plakophilin 1 gene result in ectodermal dysplasia/skin fragility syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11841538" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Compound heterozygosity for non-sense and mis-sense mutations in desmoplakin underlies skin fragility/woolly hair syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19945625" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Ectodermal dysplasia-skin fragility syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25683118" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Loss-of-function mutations in CAST cause peeling skin, leukonychia, acral punctate keratoses, cheilitis, and knuckle pads.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/132904" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Hypopigmentation with punctate keratosis of the palms and soles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24075184" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Cole Disease Results from Mutations in ENPP1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22265016" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : RHBDF2 mutations are associated with tylosis, a familial esophageal cancer syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26419362" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Tylosis with oesophageal cancer: Diagnosis, management and molecular mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29765964" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : A Rare Syndrome Resembling Scleroderma: Huriez Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29409814" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : SMARCAD1 Haploinsufficiency Underlies Huriez Syndrome and Associated Skin Cancer Susceptibility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29409814" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : SMARCAD1 Haploinsufficiency Underlies Huriez Syndrome and Associated Skin Cancer Susceptibility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24136893" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25886873" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Olmsted syndrome: clinical, molecular and therapeutic aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34121213" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Japanese guidelines for the management of palmoplantar keratoderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17298101" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Acquired palmoplantar keratoderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28929614" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Plantar keratoderma climatericum: Successful improvement with a topical estriol cream.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2943612" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Keratoderma climactericum (Haxthausen's disease): clinical signs, laboratory findings and etretinate treatment in 10 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30484821" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Association of Transient Palmoplantar Keratoderma With Clinical and Immunologic Characteristics of Bullous Pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30007013" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Bullous pemphigoid with hyperkeratosis and palmoplantar keratoderma: Three cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30216406" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Management of congenital ichthyoses: European guidelines of care, part one.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29500825" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Case of punctate palmoplantar keratoderma type I treated with combination of low-dose oral acitretin and topical salicylic acid and steroid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28008647" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Palmoplantar Keratoderma in Costello Syndrome Responsive to Acitretin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25313946" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Low-dose acitretin in Papillon-Lefèvre syndrome: treatment and 1-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26617313" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Alitretinoin: treatment for refractory palmoplantar keratoderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30339730" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Alitretinoin in punctate palmoplantar keratoderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25037811" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Alitretinoin: a new treatment option for hereditary punctate palmoplantar keratoderma (Brauer-Buschke-Fischer syndrome).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21601946" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : An appraisal of oral retinoids in the treatment of pachyonychia congenita.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16924070" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Type I hereditary punctate keratoderma associated with widespread lentigo simplex and successfully treated with low-dose oral acitretin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29469768" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : A novel association of pseudoainhum and epidermolytic ichthyosis, successfully treated with full thickness skin graft after failed z-plasty repair.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31895432" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Use of Epidermal Growth Factor Receptor Inhibitor Erlotinib to Treat Palmoplantar Keratoderma in Patients With Olmsted Syndrome Caused by TRPV3 Mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17145926" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : SiRNA-mediated selective inhibition of mutant keratin mRNAs responsible for the skin disorder pachyonychia congenita.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17762855" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Development of therapeutic siRNAs for pachyonychia congenita.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29106929" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Gentamicin-Induced Readthrough and Nonsense-Mediated mRNA Decay of SERPINB7 Nonsense Mutant Transcripts.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
